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1 Summary 
Synthetic biology explores the means of redesign and fabrication of existing biological 
systems or the de novo design and generation of biological components that are 
entirely new to nature. The main focus of the relatively new and dynamic discipline is 
to develop programmable genetic regulatory systems. Precise, reversible and 
temporary control of gene expression as well as in-depth understanding of 
fundamental genetics are crucial for the programming of new genetic circuits. 
RNA represents one of the most powerful substrates in the engineering of biological 
systems, as it is versatile, designable and easily characterizable. Among the diverse 
functions of RNA molecules, their role as natural riboswitches has predominantly 
inspired researchers to design synthetic RNA-based regulators. Most of RNA devices 
contain a sensor element, an aptamer domain, which recognizes small molecules or 
protein ligands with high specificity and affinity, and an expression platform, controlling 
gene expression via various mechanisms. Generally, binding of a specific ligand to the 
aptamer domain stabilizes the RNA molecule or causes conformational changes in its 
structure; these further regulate transcription, translation and mRNA processing and 
degradation. Engineered RNA-based devices have already demonstrated multiple 
applications in synthetic biology. However, their implementation was mostly validated 
in bacteria and yeast, while mammalian synthetic biology has lagged behind.  
Splicing of pre-mRNAs is an essential process in human cells that generates a diverse 
proteome through networks of coordinated splicing events and offers an additional 
layer of control for synthetic RNA devices. The reprogrammed removal of intronic 
sequences could provide a novel approach for the development of gene therapies to 
tackle disease phenotypes. For this purpose, it is necessary to design tools that allow 
precise and timely control of the splicing mechanisms. In the first research project 
described in the presented doctoral thesis, a versatile and highly efficient splicing 
device enabling control of gene expression in human cells and making use of an RNA 
aptamer recognized by the TetR was designed. Further, the portability of the splicing 
device was shown through its functionality in various reporter systems and the 
endogenous gene context. In the course of the thesis, the first inducible model for 
alternative 3’ splice site recognition with the tetracycline repressor (TetR) aptamer 
leading to production of splice variants with different subcellular localization was 
generated. The applicability of the system was corroborated in experiments aimed at 
controlling nuclear import in human cells. The proposed approach may prove valuable 
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in phenotypic studies of essential genes and provide an alternative in the development 
of therapeutic strategies, as the nucleo-cytoplasmic transport is vital for the 
maintenance of balanced cell physiology, with aberrant spatiotemporal localization of 
proteins leading to the development of various disorders and cancer. Finally, the third 
research project undertaken in the course of my doctoral studies focused on the 
development and optimization of the TetR aptamer dependent translational control 
system in human cells. Translational regulation constitutes an important point of post-
transcriptional control of gene expression, enabling the cell to rapidly change the level 
of a specific gene product. Up to now, no efficient aptamer-ligand based translational 
regulatory system has been demonstrated in mammalian cells. 
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2 Introduction  
2.1 Synthetic biology 
Synthetic biology is a rising interdisciplinary research area, including biotechnology, 
genetic engineering, molecular biology, biophysics, electrical engineering, control 
engineering and evolutionary biology. One of the aims of the field is to engineer new 
living functionalities by creating, characterizing, and assembling biological parts, 
devices, and systems in living cells. The ability to re-engineer living organisms has 
immense potential to address societal needs with a number of applications, ranging 
from energy, to environment, and to medicine 1, 2. 
Synthetic biology is based on scientific progress in biology which occurred over the 
past 50 years, especially DNA cloning, amplification and sequencing techniques as 
well as the transformation or transfection possibility to insert foreign DNA within a cell 
3, 4 (Figure 2.1). The discovery that the rate of gene expression can be controlled by 
transcription factors, allows it to view genes as dynamical systems with inputs and 
outputs, where inputs and outputs are proteins. These parts can thus be assembled to 
form functional modules and larger systems. In fact, the properties of these 
components are often altered by the nucleic acid sequences of the genetic elements 
surrounding them. The design of the first two synthetic genetic circuits, a ring-oscillator 
and a toggle switch in the year 2000 was based on these technologies 5, 6. At this time, 
much work was focused on the combination of a few DNA parts to form simple circuit 
modules with the aim of understanding the purpose of similar naturally occurring 
motifs. The synthetic biology has progressed to a “systems view” of biological 
processes, focusing on generating larger systems composed of well-characterized 
parts and subsystems. Theoretically, an ideal designed synthetic device should 
maintain its input/output behaviour as characterized in isolation unchanged upon 
combination with other modules and be transferable between bacteria to yeast and 
mammalian cells 7. Failure of modularity leads to a long and repeated design process 
where subsystems are re-engineered from scratch any time a new module is added, 
thus presenting a challenging obstacle to scaling up circuits’ size. Currently, intense 
research has gone into strategies for enabling modular and layered design, what it is 
important to set the basis for the rational design of systems that are sophisticated 
enough to solve real-world problems. For this purpose, the scientists have made 
considerable efforts toward creating novel parts, characterizing existing parts, 
 Introduction 
[4] 
providing insulation between modules, and enforcing functional circuit modularity 
against the effects of loads through the design of load drivers 1, 8, 9. 
Figure 2.1 Synthetic biology on the temporal axis. (left) Enabling science: DNA cloning tools. 
(middle) Modules era: the first synthetic systems created were simple modules performing tasks such 
as oscillations and switching. (right) Systems era: construction of more complex circuits is based on a 
modular/layered design approach (adapted from 1). 
2.1.1 Applications of synthetic biology to health 
Synthetic biology can revolutionize disease and cancer diagnosis and treatment. 
Synthetic devices can sense the intracellular concentrations of multiple molecular 
species, carry out logic computations through biomolecular reactions, and output a 
visible signal when a set of logic conditions are met 1, 10. These logic conditions can be 
designed to classify the chemical signature typical of cancer cells, so that the circuit 
can recognize cancer and trigger a number of actions 11 (Figure 2.2A). Synthetic 
genetic circuits can program bacteria to colonize target sites where cancer is detected, 
providing a promising approach to reduce invasive tests for diagnosis and health 
monitoring 12, 13. Programmed bacteria can further serve as smart vehicles for drug 
delivery by lysing at the tumour site and releasing therapeutic proteins to reduce 
tumour activity (Figure 2.2B). Synthetic biology also provides powerful tools to program 
immune T cells, to specifically attack cancer cells 14 (Figure 2.2C). Synthetic receptors 
engineered on T cells combined with biomolecular logic gates can identify cancer cells 
with high specificity.  
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Figure 2.2 Applications of synthetic biology to health (A) A multi-input cell type classifier circuit used 
for cancer diagnostic ex vivo. A reference profile of miRNAs that are expressed in cancer cells is used 
to construct a genetic logic circuit realized through RNA interactions. When transfected into a cancer 
cell, the output of the logic circuit triggers expression of a fluorescence protein. (B) Bacteria can be 
engineered to periodically release a drug in vivo. A consortium of engineered bacteria is delivered to the 
target tumour site. Each cell contains a genetic clock, a cell lysis gene, a therapeutic protein production 
gene and a cell-cell communication module. The synchronized clocks control cell lysis in a periodic 
manner to release the therapeutic proteins, resulting in periodic drug delivery to the patient. (C) Synthetic 
genetic circuits increase the specificity and safety of cancer immunotherapy. Receptors can be 
engineered to trigger T cell activity when cancer cells are detected. Feedback loops can be used to limit 
the response of T cell activity to avoid side effects. (D) A synthetic lineage control circuit, activating the 
expression of three transcription factors according to a temporal pattern, hIPSCs can be reprogrammed 
into insulin-secreting beta-like cell for treating diabetes (adapted from 1). 
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Synthetic controllers can then interact with the cellular chemotaxis pathway to migrate 
T cells to tumour cites. After T cells reach the target site, in vivo genetic controllers can 
actuate negative feedback actions to regulate the duration and strength of T cell activity 
to protect non-cancerous cells. Synthetic biology may also be used to enhance 
understanding of natural systems, including understanding of cell fate decisions and 
can provide tools to reprogram cell fate for regenerative medicine (Figure 2.2D). It was 
demonstrated that a synthetic reprogramming circuit that converts pancreatic 
progenitor cells derived from human induced pluripotent stem cells (hIPSCs) into 
insulin-secreting beta-like cells by strictly regulating the timing and expression of three 
key transcription factors in vivo 15. To summarize, synthetic biology could prove 
remarkably effective in regenerative medicine where some damaged tissues and 
organs are traditionally replaced by biomaterials to restore proper function. These and 
many more tissues could instead be replaced by patient-derived cells that have been 
re-programmed through appropriate temporal and spatial control, avoiding innate 
immune responses.  
 
2.2 The potential of aptamers as synthetic elements for regulating gene 
expression 
2.2.1 Trans-regulatory RNAs 
A main objective of synthetic biology is the specific control of cellular behaviour to 
understand fundamental genetics. Precise, reversible and temporary control of gene 
expression is necessary and can be achieved at the transcriptional, translation and 
post-translational levels 16, 17. RNA is not only an intermediate for the conversion of 
gene expression to protein synthesis but also provides an attractive molecular scaffold 
for the design of genetic control elements. By interacting with ligands, RNA can alter 
its shape to act as a switch inside the cell 18, 19. Moreover, RNA-based systems allow 
fast regulatory responses, genetic modularity and portability, features that make them 
suitable for complex platforms to achieve a broad spectrum of regulatory outputs 20, 21, 
22. RNA utilizes various mechanisms to control gene expression. One example of trans  
regulators represent non-coding RNAs (ncRNAs) which can have specialized functions 
in diverse biological processes and can shape nuclear structure and regulate gene 
expression. ncRNAs are divided into long (lncRNAs) and short (sRNAs) groupings. 
lncRNAs can act at various levels of gene expression and their functions are highly 
diverse. Many lncRNAs perform their functions by interacting with enhancers, 
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promoters, and chromatin-modifying complexes to regulate the transcriptional level. 
These interactions are mediated by specific short RNA sequence motifs or larger 
secondary or tertiary structures 23, 24.  Additionally, lncRNAs interacts with microRNAs 
(miRNA) networks in order to control gene expression at the post-transcriptional level.  
Small RNAs (sRNAs) that have been identified in bacteria, where they help to respond 
to changes in the environment 25, 26. Generally, sRNAs regulate their target mRNAs 
through limited base pairing interactions, which leads to further changes in mRNA 
translation and stability, and consequently influences target gene expression. RNA-
mediated regulations are also widespread in eukaryotes, where single-stranded 
miRNAs inhibit mRNA translation and double-stranded short interfering RNAs 
(siRNAs) can cleave mRNAs 27. Another class of sRNAs represent Piwi-interacting (pi) 
RNAs. The piRNAs form complexes with Piwi proteins regulating transposable 
elements through an RNA-dependent DNA methylation mechanism in germline cells 
28. Moreover, the CRISPR-Cas9 system has provided another class of highly efficient 
tools to perform gene regulation with the use of guide RNAs 29.  
 
2.2.2 Cis-regulatory RNAs 
Riboswitches are an extraordinary example class, as they are cis-regulatory structured 
RNA elements capable of controlling expression of downstream genes by direct 
response to a small molecule ligand 30, 31. The first riboswitch binding a flavin 
mononucleotide was discovered in the 5’ UTR (untranslated region) of prokaryotic 
mRNA by Breaker 32. Riboswitches include a ligand-sensing domain called an 
aptamer, and a regulatory domain, called the expression platform. Ligand binding to 
the aptamer stabilizes the aptamer structure and causes a conformational change or 
other activation mechanism in the expression platform, which mediates gene 
regulation 33. In bacteria, riboswitches control transcription by forming a terminator or 
anti-terminator stem, or control translation by either occluding or exposing the 
ribosomal binding site (RBS or Shine-Dalgarno (SD) element) sequence that needs to 
be recognized by the ribosome during translation. A uncommon mechanism involves 
ligand-mediated ribozyme activation. It has been observed that ligand binding activates 
self-cleavage of the glutamine-fructose-6-phosphate amidotransferase RNA, leading 
to mRNA degradation 34.    
So far it is still unclear how widespread riboswitches are. Riboswitch-based gene 
control is prevalent in bacteria, regulating approximately 2% of all genes in the bacteria 
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species Bacillus subtillis 35. More than twenty distinct classes of natural aptamers are 
currently known that showcase the capability of the aptamers for selective and tight 
recognition of diverse compounds in cells. Many various genes are regulated by 
riboswitches. Most of riboswitches inhibit the production of unnecessary biosynthetic 
enzymes or transporters when a compound is already present at sufficient 
concentration. Moreover, some riboswitches can activate the expression of salvage or 
degradation pathways when their target molecules are present in excess 36, 37. 
Although, most of these riboswitches have been identified in bacterial species, the 
coenzyme thiamine pyrophosphate-sensing riboswitches have been found in fungi and 
plants and it represents the most widespread riboswitch class discovered to date  19, 
38, 39. 
 
2.2.3 Riboswitches as genetic control devices 
Engineered riboswitches known so far exploit RNA aptamers as a core component. 
Aptamers are capable of binding nearly any ligand of choice with high affinity and 
specificity and can be selected in vitro by directed evolution (SELEX: systematic 
evolution of ligands by exponential enrichment) which has led to the rapid and 
prevalent application of engineered riboswitches as artificial genetic control devices in 
synthetic biology over the past decade 18. In classical SELEX, a pool of usually 1014 
randomized sequences is mixed with an immobilized target. Non-binding molecules 
are removed by washing whereas bound molecules are eluted, amplified and 
subjected to next rounds of selection 33. Gradually increasing the stringency during the 
following cycles may lead to aptamers that bind with high affinities and discriminate 
between closely related compounds. To date, aptamers targeting amino acids, 
proteins, small metal ion, organic molecules, bacteria, viruses, whole cells and animals 
have been generated. These aptamers have been widely applied in analytical, 
bioanalytical, imaging, diagnostic and therapeutic fields 40. 
 
A major benefit of riboswitches is the possibility to combine sensing, transmitting and 
regulating domains within one molecule, enabling a direct approach to engineering 
synthetic devices with desired and defined functions. However, only a few aptamers 
have the properties that allow their exploitation as sensing domains of riboswitches 41 
42. Natural aptamer domains are conserved in secondary structure over bacterial phyla 
and the associated expression platforms can differ in both sequence and mode of 
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action between species. Therefore, engineering expression platforms requires choice 
of regulatory mode and fine-tuning of allosteric regulation, which often cannot be done 
rationally. The difficulty in design results from a limited information on ligand-free 
structures of riboswitches and also from a few full riboswitch structures that include the 
expression platform, as opposed to just the aptamer domain 19, 22.  
 
In bacteria, engineered riboswitches most often target translation initiation, either by 
controlling access to the RBS through helix slippage or by sequestering the RBS 19 
(Figure 2.3A). Regulation of gene expression by a theophylline-mediated translational 
switch efficiently allowed the control of chemotaxis in Escherichia coli 43. However, only 
recently transcriptionally-based synthetic riboswitches have been documented and in 
this case a transcriptional terminator is formed depending on the binding state of the 
aptamer 44, 45, 46 (Figure 2.3B).  
The cleavage activity of small ribozymes, like the hammerhead ribozyme have proved 
to be versatile tools in synthetic biology. Engineered allosteric aptazymes comprised 
of a self-cleaving ribozyme and an RNA aptamer have been exploited to achieve 
ligand-dependent regulation of gene expression via a variety of mechanisms in 
prokaryotic and eukaryotic cells 47, 48, 49. In bacteria, the aptazymes were used to 
liberate the ribosomal binding site after ligand-dependent ribozyme cleavage (Figure 
2.3C).  
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Figure 2.3 Mechanisms of engineered riboswitches in bacteria. (A) Regulation of translation. In the 
absence of a ligand, a stem-loop structure is formed between the aptamer domain (in green) and a 
sequence element complementary to the Shine-Dalgarno (SD) sequence (pink). Thus, the SD sequence 
(orange) is accessible for 30S binding and translation initiation occurs. As a consequence of ligand 
binding (in blue) and folding of the aptamer domain, an alternative stem-loop is formed which sequesters 
the SD sequence, blocking the binding of the 30S ribosomal subunit. (B) Regulation of transcription. 
The aptamer domain is fused to a short spacer region (gray), followed by a sequence complementary 
to the 3’ part of the aptamer (pink) and a U stretch. In the absence of a ligand, the complementary 3’ 
part is base-paired with the aptamer forming a terminator structure; thus, RNA polymerase (RNAP) 
dissociates and transcription is terminated. Upon ligand binding, terminator structure formation is 
inhibited and transcription can proceed, resulting in expression of the reporter gene. (C) Regulation with 
apatzyme. A ligand-dependent aptazyme is inserted into the 5’ UTR of an mRNA in a way that ligand-
induced self-cleavage liberates a sequestered SD sequence to induce translation initiation (adapted 
from 31). 
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In eukaryotes, translational regulation by engineered riboswitches functions differently 
33. Insertion of the aptamer into a eukaryotic 5’ UTR region leads to inhibition of 
translation initiation, either by preventing binding of the small ribosomal subunit to the 
mRNA cap structure or by interfering with ribosomal subunit scanning for the AUG start 
codon (Figure 2.4A). Several groups demonstrated translation control with aptamers 
which specifically recognize a Hoechst dye, malachite green, tetracycline, neomycin, 
biotin or theophylline 50, 51, 52, 53. Additionally, a cap-independent translation initiation 
by an internal ribosome entry site has also been controlled by engineered riboswitches 
54. The only naturally occurring eukaryotic riboswitches have been discovered in 
filamentous fungi, green algae and higher plants where they control gene expression 
via regulation of pre-mRNA splicing 55, 56, 57, 39. Analogously, theophylline- or 
tetracycline-binding aptamers have been used to block splicing by placing them close 
to either the 5’ splice site, the 3’ splice site or the branch point sequence 58, 59, 60, 61 
(Figure 2.4B).  
Aptazyme-based control of gene expression in yeast and mammalian cell lines using 
hammerhead ribozymes (Figure 2.4C) has been demonstrated by several groups 62, 
63, 64. Aptazyme cleavage at the 5’ UTR leads to loss of the 5’ cap, preventing ribosome 
initiation while aptazyme activity at the 3’ UTR leads to loss of the poly-A tail, favouring 
degradation of the mRNA transcript. These aptazymes can activate or repress gene 
expression, depending upon whether the small molecule ligand turns the ribozyme on 
or off. Apart from the hammerhead ribozyme, the hepatitis delta virus ribozyme has 
also been successfully applied to RNA engineering 65.  
RNA interference (RNAi) is an important and widely used mechanism in eukaryotes to 
repress gene expression. RNAi controls a broad range of developmental and 
physiological processes and it is also a standard system in molecular biology with a 
possible therapeutic strategy 66, 67. Consequently, attempts to control the biogenesis 
pathway of RNAi were demonstrated with TetR or theophylline aptamers or aptazymes 
at sites of siRNA or shRNA molecules where their presence can interfere with 
processing by either Drosha or Dicer 68, 69, 70, 71 (Figure 2.4D).    
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Figure 2.4 Mechanisms of engineered riboswitches in eukaryotes. (A) Regulation of translation. 
After insertion of the aptamer (in green) into the 5’ UTR of a mRNA, ligand binding (in blue) to the 
aptamer prevents scanning of the 40S ribosomal subunit and, consequently, translation initiation. (B) 
Regulation of pre-mRNA splicing. An aptamer is placed into an intron of a eukaryotic mRNA to control 
the accessibility of the 5’ splice site (SS). Ligand binding blocks splicing. (C) Regulation with aptazyme. 
A ligand-dependent aptazyme is inserted into the 5’ UTR. Ligand-induced self-cleavage triggers RNA 
degradation (pink pacman). (D) Regulation of RNA interference. An integrated aptamer domain (green) 
interferes in its ligand-bound state with the enzymatic activity of Dicer (adapted from 31). 
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2.2.4 RNA binding proteins (RBPs)-based synthetic RNA devices  
Several successful attempts demonstrate conditional gene expression with synthetic 
RNA devices 31. Among others, RNA binding proteins (RBPs) were used to predictably 
influence gene expression that both increases the number of cellular functions 
available for regulation while also enhancing the precision of the regulation 72. One 
example of a protein-responsive RNA switch that controls translation in mammalian 
cells is based on the interaction between the ribosomal protein L7Ae and the box C/D 
kink-turn 72. In other studies the L7Ae and the bacteriophage coat protein MS2 were 
used to design microRNA high- and low-sensors to engineer complex circuits in 
mammalian cells 73. The next example of a RBP device was developed to control 
alternative splicing 74. RNA structures recognised by proteins involved in NFkB and 
Wnt signalling were used to control cell fate through exon skipping. Thus, the 
expression of herpes simplex virus-thymidine kinase that confers sensitivity to a pro-
apoptosis drug was controlled. Another interesting example of an RBP-based switch 
makes use of Pumilio and its derivatives, such as Pumilio and FBF (PUF) protein that 
can bind to RNA. The PUF domain has been fused with a splicing regulatory domain 
to regulate gene expression, primarily by controlling exon skipping 75, 76. 
 
2.2.5 The tetracycline repressor (TetR) and the TetR-binding aptamer 
The Tet systems in eukaryotes are derived from the transposon Tn10 tetracycline (tc)  
resistance operon and it represents the most common method for inducing eukaryotic 
gene expression, for both, in vivo and in vitro applications. The prokaryotic Tet system 
was modified to be operative in eukaryotic cells 77. It is based on the tc repressor 
(TetR), whose ligand is the antibiotic tc or several of its derivatives 68. TetR is one of 
the most studied transcriptional regulators. It is genetically, biochemically and 
structurally well characterized and belongs to the Tet/Cam family of bacterial 
regulators. TetR controls the expression of the Tn10 encoded tc resistance in Gram-
negative bacteria. The actual resistance protein TetA is the an antiporter that actively 
export the tc out of the cell. The constitutive expression of TetA protein is toxic to the 
cell. Therefore, in the absence of this antibiotic TetR prevents the transcription of tetA. 
TetR is a 46.6 kDa homodimer with N-terminally located helix-turn-helix motifs 78, 79 
(Figure 2.5A). In the absence of a ligand, TetR forms a dimer that strongly binds to the 
tet operator sequence (tetO). In the presence of a ligand TetR dissociates from the 
DNA, and gene expression is activated 80. In mammalian cells, TetR can be used as 
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both a repressor (Tet-OFF), or converted into an activator (Tet-ON) by fusing it to the 
transactivation domain from virion protein 16 of the Herpes simplex virus. This system 
was initially developed for applications in model organisms where the tools for 
controlling gene expression are limited. More recently, homologues of TetR have been 
used to build synthetic gene switches for various applications and switches responding 
to other antibiotics 81. The RNA aptamer recognized by the TetR was found by 
combining in vitro selection with in vivo screening in Escherichia coli 82. The TetR 
aptamer folds into a stem-loop structure with an internal loop that displays the protein-
binding site, while the P1 and P2 stems can be easily modified (Figure 2.5B).  
 
Figure 2.5 The tetracycline repressor (TetR) and the TetR-binding aptamer. (A) Crystal structure of 
the TetR-tetO complex. The two monomers are shown as yellow/green ribbons, two helix-turn-helix 
motifs are in blue and the DNA is displayed in red (adapted from 78). (right) Structures of tetracycline 
and the derivate doxycycline (adapted from 83). (B) In-line probing and the secondary structure of the 
TetR binding aptamer. Nucleotides involved in binding are shown in red (adapted from 82). 
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The affinity of the TetR aptamer complex is extremely high and corresponds to that of 
the TetR bound to the tetO operator DNA 84. Binding of tc or doxycycline (dox) to TetR 
leads to conformational changes within the protein resulting in DNA and RNA release, 
respectively, and consequently allows ligand-dependent reversible binding 85. The 
applicability of the TetR aptamer system for the control of gene expression has been 
already confirmed by various approaches in different organisms. The aptamer was first 
used to activate TetR-controlled transcription in E. coli by displacing TetR from its DNA-
binding site 82. Next, portability and broader applicability of the system was 
documented with its successful use in the protozoon Plasmodium falciparum and in 
yeast 86, 87. Further, an additional layer of regulation was added to the TetR aptamer 
system with the design of a theophylline-responsive TetR aptamer that proved 
functional 88. Our group recently used the TetR aptamer to control miRNA biogenesis 
in human cells 68. These approaches highlight the universal nature and potential of the 
TetR aptamer as a regulatory element.  
 
2.3 pre-mRNA splicing  
Most eukaryotic genes are expressed as precursor mRNAs (pre-mRNAs) that are 
converted to mRNA by splicing, an important step of gene expression in which introns 
must be removed and exons ligated together in order to produce correct mRNA. The 
accuracy of the splicing process involves the recognition of short sequences at 5’ splice 
site (5SS) and 3’ splice site (3SS) within the pre-mRNA that delimit the exon-intron 
boundaries 89. The 3SS includes three sequence elements: the branch point sequence 
(BP), the downstream polypyrimidine (Py)-tract and the 3SS itself encoded by the 
dinucleotide AG. The splice sites sequences have shown a higher level of conservation 
in budding yeast compared to those in metazoans (Figure 2.6A). Introns are removed 
by two consecutive transesterification reactions (Figure 2.6B). First, the 2′ OH group 
of the BP adenosine carries out a nucleophilic attack on the 5SS. This splits the 
substrates into the upstream exon and the downstream RNA, in which the 5’ of the 
intron is attached to the BP adenosine, forming a lariat structure. Second, the 3SS is 
attacked by the 3′ OH group of the 5′ exon, leading to the ligation of the 5′ and 3′ exons 
generating the mRNA and release of the intron. This process is catalysed by the 
spliceosome, and it is probably the most complex enzyme of the cell 90, 91.   
 
  Introduction   
 
[16] 
 
 
Figure 2.6 pre-mRNA splicing. (A) Conserved sequence elements of mammalian and yeast pre-
mRNAs. Exons (in blue) separated by an intron (gray). The consensus sequences at the 5’ splice site 
(5SS), the branch point sequence (BP), the polypyrimidine (Py)-tract and 3’ splice site (3SS) are shown. 
N means any nucleotide, R is a purine, and Y is a pyrimidine. (B) Two steps of the transesterification 
reactions of pre-mRNA splicing (adapted from 89).  
 
The U2-dependent spliceosome contains the U1, U2, U5, and U4/U6 small nuclear 
ribonucleoproteins (snRNPs) and a large number of non-snRNP protein factors. Each 
snRNP is composed of a single uridine-rich small nuclear RNA (snRNA) and multiple 
proteins. Spliceosome assembly occurs by the ordered interaction of the spliceosomal 
snRNPs and numerous other splicing factors (Figure 2.7). Spliceosome assembly is 
highly dynamic in that complex rearrangements of RNA:RNA, RNA:protein, and 
protein:protein interactions take place within the spliceosome. For introns with the 
length of ~200-250 nt, the spliceosome initially assembles across the intron. In the 
earliest cross-intron spliceosomal complex (the E complex), the U1 is recruited to the 
5SS and factors such as SF1/mBBP and U2AF interact with the branch point sequence 
(BP) and Py-tract, respectively. Next, the U2 stably associates with the BP, forming 
the A complex. The U4/U6·U5 tri-snRNP, which is pre-assembled from the U5 and 
U4/U6, is further recruited, generating the pre-catalytic B complex. Main 
rearrangements in RNA-RNA and RNA-protein interactions, leading to the 
destabilization of the U1 and U4, generate the activated spliceosome (the Bact 
complex). Next, catalytic activation by the DEAH-box RNA helicase Prp2, produces 
the B* complex, which catalyses the first of the two steps of splicing. This generates 
the C complex, which further catalyses the second step. The spliceosome then 
dissociates and, after some remodelling, the released snRNPs participate in other 
rounds of splicing 89, 90, 92.  
Most mammalian genes contain multiple introns whose sizes differ from several 
hundred to several thousand nucleotides, whereas their exons have a more fixed 
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length of ~120 nt 93. When intron length exceeds ~200-250 nt splicing complexes first 
form across an exon in a process called exon definition 94. During exon definition, the 
U1 binds to the 5SS downstream of an exon and promotes the association of U2AF 
with the 3SS upstream of it which next leads to the recruitment of the U2 to the BP 
upstream of the exon. Splicing enhancer sequences within the exon recruit proteins of 
the SR protein family, which create a network of protein-protein interactions across the 
exon that stabilize the exon-defined complex. As the chemical steps of splicing occur 
across an intron, next from exon definition the 3SS must be paired across the adjacent 
intron with an upstream 5SS. The cross-exon interactions are first disrupted and the 
cross-exon complex is then converted into a cross-intron A complex, where a 
molecular bridge now forms between U2 and U1 bound to an upstream 5SS. This step 
is important in determining which 5′ and 3′ exon will finally be spliced. The switch from 
an exon-defined to intron-defined splicing complex is still poorly understood and 
probably leads to regulation of exon inclusion or skipping during alternative splicing 
evens 89, 95.  
 
Figure 2.7 Pre-mRNA splicing circle. Pre-mRNA splicing is catalysed by the spliceosome, a 
multimegadalton ribonucleoprotein (RNP) complex comprised of five snRNPs (U1, U2, U5, U4/U6) and 
numerous proteins factors. Details description in the text (adapted from 89). 
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2.3.1 Alternative splicing  
Alternative splicing (AS) of pre-mRNA joins of different 5SS and 3SS, allowing one 
gene to express various mRNAs that encode proteins with diverse and even 
antagonistic functions 92. AS in mammals is one of the most important cellular 
processes and mainly responsible for the diversity of the human proteome. Nearly 90% 
of the human genes are subjected to alternative splicing and disruption of the splicing 
machinery may lead to genetic diseases and cancer 96. The main types of alternative 
splicing patterns (Figure 2.8) include the inclusion of alternative first and last exons, 
exon skipping (or cassette exon), intron retention, alternative 5SS and 3SS and more 
complex AS events that include mutually exclusive events, alternative transcription 
start sites and multiple polyadenylation sites. Exon skipping is the most common AS 
event in mammals. However, recent reports demonstrate that intron retention is also 
very frequently in human, occurring in nearly 75% of genes, and is a co- or post-
transcriptional mechanism designed to reduce transcript levels during development 93, 
97.  
 
 
Figure 2.8 Types of alternative splicing. In all examples of AS the constitutive exons are shown in 
orange and the alternatively spliced regions in blue. Introns are represented as solid lines and thin lines 
indicate splicing events (adapted from 97). 
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AS generates fragments of mRNA variability that can insert or remove amino acids, 
shift the open reading frame, or introduce a premature termination codon. Additionally, 
AS may influence gene expression by removing or inserting regulatory elements 
controlling translation, mRNA stability, or cellular localization. AS is strictly regulated 
in a cell type, developmental stage, gender or response to external stimuli manner. 
Splice site selection must therefore be precisely regulated in time and space. AS 
regulation is coordinated by intronic repressor and activator cis-elements distinct from 
the classical splicing sequences. Consequently, these elements serve to enhance or 
inhibit recognition of the classical splice sites by the core spliceosome. However, it is 
unclear why activation dominates in one cell type while repression dominates in 
another. Mutations that perturb this balance may disrupt AS and produce protein 
isoforms inappropriate for a cell type or developmental stage 97, 98. Full understanding 
of alternative and constitutive splice sites selection is complicated as features of 
regulatory sequences and splice site signals are often short and degenerate. 
Moreover, the best bioinformatic tools are only 50% precise in predicting actual splice 
sites over frequent and similar sequences that are not used. About 50% of the 
documented mutations result in aberrant splicing. Some have been reported to disrupt 
splicing by creating a new splice site or by interfering with splicing regulatory elements. 
Splicing mutations then may play a more important role than previously though in 
human hereditary disease and cancer 99, 100, 101, 102. Reprogramming of aberrant 
splicing could provide a novel approach for the development of gene therapies to tackle 
disease phenotypes. For this purpose, it is necessary to engineer tools that allow 
precise and timely control of the splicing process.  
 
2.3.2 Splicing control with aptamers 
The only documented natural riboswitches found in eukaryotes are thiamine 
pyrophosphate riboswitches in plants and filamentous fungi 55,56,57,39. Eukaryotic 
riboswitches regulate gene expression through AS (Figure 4.2B). In these examples 
the aptamer masks a 5SS, causing an alternative 5SS selection. In the presence of a 
ligand the 5SS is unmasked, causing inclusion of an alternative exon which 
consequently leads to translation of an upstream open reading frame or inclusion of a 
premature stop codon. In higher plants, the aptamer located in the 3’ UTR sequesters 
both 5 and 3SS, leading to inclusion of a polyadenylation sequence and a mature RNA 
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transcript and in the presence of a ligand both SS are unmasked, leading to removal 
of the polyadenylation sequence and consequently a transcript degradation. 
Splicing regulation by RNA-based systems has been demonstrated in yeast and 
mammalian cells. Suess group has shown an inhibition of pre-mRNA splicing mediated 
by the tc aptamer in yeast 60. The tc aptamer is inserted in a way that the consensus 
sequence of 5SS is integrated within the closing stem of the aptamer. The 5SS is 
recognized by the U1 only in the absence of tc. A regulatory factor was achieved up to 
16-fold. It is a highly efficient aptamer-based conditional gene regulation system in
yeast and attempts to transfer it into human cell lines failed so far. Gaur and co-workers
have shown splicing inhibition through theophylline-sequestering of branch point
sequence and 3SS 58, 59. In an in vitro splicing assay a 4-fold reduction of gene
expression is observed upon addition of theophylline. In HeLa cells the effect was not
strong enough to influence a switch in splicing site choice. Smolke group has used
MS2 system to control cell fate through exon skipping to regulate the expression of
herpes simplex virus-thymidine kinase in human cells 74. Currently, an exon skipping
control with tc-aptamer by blocking a 3SS was demonstrated 61. However, the
regulatory effect of these devices was modest (~2- to 4-fold). Despite the extraordinary
importance of AS for gene regulation, the number of synthetic splicing devices is fairly
limited and suggests that the full potential for their development has been far from
realised to date.
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3 Scope 
The field of synthetic biology strives to apply engineering principles to the design and 
build-up of biological systems for defined purposes. At the heart of all of synthetic 
biology applications is the precise control of gene expression – turning the right gene 
on at the right time and at the right level. The RNA-based gene regulators constitute a 
fundamental component of the synthetic biology ‘toolbox’. Combination of versatility, 
designability and easy characterization makes RNA the most powerful substrate for 
the engineering of gene expression within cells. To date, the most substantial progress 
in functionality of RNA-based devices has been demonstrated in microorganisms, 
while even the best mammalian systems are burdened with lower gene regulation 
efficiency than their bacterial counterparts, necessitating the development of tools 
specific to these types of cells. Precisely tuned human gene expression control with 
synthetic RNA regulators may enable a wide range of practical applications in the realm 
of life sciences. 
Therefore, the focus of the studies undertaken in course of preparation of my doctoral 
thesis was the design and development of versatile, robust and reversible RNA-based 
devices active in human cells through engineering and exploiting the potential of the 
TetR aptamer as a key synthetic element. Three strategies to use the TetR aptamer to 
control protein output by intron retention, alternative 3’ splice sites and regulation of 
translation have been explored. The following sections of the hereby presented thesis 
describe application and universality of the TetR aptamer in human synthetic biology. 
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4 Results 
4.1 Project I: Universal splicing module based on TetR aptamer to control gene 
expression in human cells 
Fine-tuning of gene expression is desirable for a wide range of applications in synthetic 
biology and medicine and to this purpose RNA regulatory devices can be applied 8, 17, 
18, 19. Splicing of pre-mRNAs is an essential process in mammalian cells that generates 
a highly diverse proteome through networks of coordinated splicing events. 
Reprogramming of aberrant splicing could provide a novel approach for the 
development of gene therapies to tackle disease phenotypes. Towards this purpose, 
it is necessary to engineer tools that allow precise and timely control of the splicing 
process. Despite the extraordinary importance of alternative splicing for gene 
regulation, the number of synthetic splicing devices is fairly low 74, 59, 61 and suggests 
that the full potential for their development has been far from realized to date. The aim 
of this project was to designed a versatile and highly efficient TetR Splicing Device 
(TSD) for controlling gene expression in human cells that makes use of an RNA 
aptamer that is recognized by the TetR aptamer 82. Portability of the splicing device 
was shown through its functionality in different reporters and endogenous gene 
context.  
 
4.1.1 Results 
The 53 nt long TetR aptamer was used to set up a switching device to control intron 
retention. The overall idea was to place the aptamer close to the 5SS in a way that 
binding of TetR to the aptamer would efficiently inhibit splice site recognition. 
Consequently, the intron is retained. Addition of dox then releases TetR from the 
aptamer freeing the 5SS resulting in correct splicing (Figure 4.1A). We made use of a 
previously established system for the firefly luciferase (FLuc) gene 103. A chimeric 
intron (CI) composed of the 5SS from the first intron of human β-globin gene and 3SS 
from the intron of an immunoglobulin gene heavy chain variable region was introduced 
into the FLuc. The CI intron was designed in a way that FLuc activity only occurs when 
the mRNA is correctly spliced. Unspliced mRNA should not be exported. If it does 
escape from the nucleus, premature stop codons in every reading frame in the intron 
sequence would either lead to rapid mRNA degradation via the nonsense-mediated 
decay pathway or to translation of a truncated protein.  
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First, the influence of the position of the intron on FLuc expression was examined. 
Thirteen different positions mimicking exonic splice features were selected within the 
FLuc cDNA, which resulted in the constructs CI1-13. Next, to analyse if the TetR 
aptamer can influence 5SS recognition, the aptamer was inserted into the intron 
directly behind the 5SS, resulting in the constructs CI1T-CI13T. HEK293 cells were 
transiently transfected with these constructs together with a plasmid expressing TetR. 
TetR itself was expressed from a strong CMV promoter and modified at its N-terminus 
with a nuclear localisation signal (NLS) from c-MYC that significantly increased its 
localisation in the nucleus. The insertion of the TetR aptamer into CI influenced FLuc 
activity to a different degree. The expression of TetR lead to significant reduction of 
FLuc activity in most constructs, yet upon addition of dox FLuc activity was completely 
restored (Figure 4.1B). Only three out 13 tested positions (CI4T, CI5T and CI12T) 
exhibited a significant dynamic range of regulation (8.3-, 14.7- and 10.2-fold, 
respectively). These constructs have both a high dynamic range but also a low basal 
activity in the OFF state. Unfortunately, the constructs CI5T and CI12T also showed a 
very low overall expression level in the ON state. Therefore, the construct CI4T was 
selected for further characterisation. TetR aptamers placed 9 nt (or more) downstream 
of the 5SS had no influence, probably due to free accessibility of the splice site for U1. 
It was also modified the length and the stability of the aptamer closing stem. Only stem 
stabilities between -11 and -16 kcal/mol allow efficient regulation.  
From all tested constructs the CI4T5 turned out to be a splice switch with an 8-fold 
dynamic range (Figure 4.1C). Further, the introduction of the two mutations A15U and 
A20C that destroy TetR binding lead to a complete loss of regulation, indicating that 
switching is indeed mediated by TetR aptamer interaction (Figure 4.1D). Moreover, the 
system up to 90% with only 0.7 µM dox was activated and it was confirmed that dox 
has no influence on cell viability at the concentration used. Finally, it was demonstrated 
that TetR can also influence the responsiveness of the system in a dosage-dependent 
manner 103. 
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Figure 4.1 TetR aptamer controls intron retention. (A) Schema of the proposed model. (left) In 
absence of TetR (in yellow), U1 (in blue) can recognize the 5SS, the intron will be spliced out. (middle) 
In the presence of TetR, U1 cannot recognize the 5SS, consequently the intron is retained. (right) 
Splicing can be restored by addition of dox that leads to conformational changes of TetR and the release 
of the aptamer. Exons are displayed as boxes and intron with TetR aptamer as a line. (B) Displayed are 
the positions of the intron with TetR aptamer insertions (positions shown in nucleotides relative to the 
ATG start codon) and their effect on FLuc activity. Constructs CI1-13T were co-transfected with plasmid 
expressing TetR. FLuc activity was measured 24 h after transfection in the absence or presence of 50 
µM dox. Shown are the fluorescence values without (white bars) and with dox (black bars). Experiments 
were performed in triplicate and repeated three times with similar results. Error bars represent the 
standard deviation from the means from three independent experiments. (C) Displayed is FLuc activity 
of the CI4T5 switch in all three states. The regulatory activity for CI4T5 is shown. CI4T5 was co-
transfected with TetR and FLuc activity was measured 24 h after transfection in the absence or presence 
of 50 µM dox. (D) Mutations A15U and A20C in the aptamer destroy TetR protein binding, which leads 
to loss of switching behaviour. 
 
Under cellular conditions, synthetic regulatory devices are influenced by the sequence 
environment and/or additional cellular factors, also described as intrinsic and extrinsic 
noise. Therefore, it is always challenging to transfer regulatory devices from one 
context into another 104,105,106. The integration of the CI4T5 from FLuc into a similar 
position of a gfp gene resulted in only 2-fold regulation [data not shown]. It contributed 
further to the CI4T5 transformation into a splicing device (TSD - TetR splicing device) 
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that can be applied to any gene of interest (GOI) with constant efficiency irrespective 
of its (genomic) context. 
First, a minimal sequence of CI4T5 important for efficient switching was defined. Due 
to the short size, the complete first exon (27 nt) from CI4T5 together with the intron 
with the TetR aptamer and six nucleotides from the second exon was taken and placed 
it in front of a gfp gene (Figure 4.2A). HEK293 cells were transiently transfected with 
this construct (named SP) together with a plasmid expressing a TetR::mCherry fusion 
protein. GFP and mCherry fluorescence were monitored 24 h after transfection in the 
absence or presence of dox using flow cytometry. mCherry expression was used to 
normalize for variation in transfection efficiency. The construct exhibits a similar 
expression level as the luciferase at the ON and OFF state (18% and 3%, respectively), 
as well as dynamic range of 6.6 (Figure 4.B).  
 
 
Figure 4.2 Defining the switching sequence and influence of cryptic 5SS within CI4T5. (A) The  
switching part was placed in front of gfp and SP_cr construct with mutated cryptic 5SS, G37-C87 to 
C37-G87. Introduced mutations are marked in red and 5SS is shown in blue. (B) Displayed are the GFP 
fluorescence SP and SP_cr constructs, values without (white bars) and with dox (black bars) and above 
each construct the regulatory activity are shown. Constructs were co-transfected with TetR:mCherry. 
GFP and mCherry expression was measured 24 h after transfection in the absence or presence of 50 
µM dox with flow cytometry and mCherry expression was used to normalize for variation in transfection 
efficiency. Experiments were performed in triplicate and repeated three times with similar results. Error 
bars represent the standard deviation from the means. 
 
Next, a cryptic 5SS in the stem of the aptamer was identified that could be responsible 
for the overall expression level being so low. This site was mutated (G3C, C53G) 
generating the construct SP_cr. The new construct exhibited two times higher GFP 
expression with a dynamic range nearly remaining unchanged (Figure 4.2B). 
Additionally, it was assessed whether and to what extent the stability of the aptamer 
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influences regulation. Two constructs were designed, one with shorter and second with 
a longer closing stems (SP_cr1-3, Figure 4.3A). Whereas destabilization of the stem 
decreased the dynamic range, a stabilization of the stem resulted in improved 
switching activity (8.3- compared to 6.1-fold) and higher GFP expression of the ON 
state compared to the SP_cr (Figure 4.3B).  
 
 
Figure 4.3 Stem modifications within SP_cr. (A) The stem was truncated of 2 or 4nt, generating 
constructs SP_cr1 and SP_cr2, respectively. Additionally, the stem was stabilized cloning SP_cr3 
construct. Introduced mutations are marked in red and 5SS is shown in blue. (B) Displayed are the GFP 
fluorescence for all constructs, values without (white bars) and with dox (black bars) and above each 
construct the regulatory activity are shown. Constructs were co-transfected with TetR:mCherry. GFP 
and mCherry expression was measured 24 h after transfection in the absence or presence of 50 µM 
dox with flow cytometry and mCherry expression was used to normalize for variation in transfection 
efficiency. Experiments were performed in triplicate and repeated three times with similar results. Error 
bars represent the standard deviation from the means. 
 
However, the GFP expression of the construct is still only 50% compared to the wild 
type GFP expression. We speculated that the weak intron removal can be due to 
exonic splicing silencers (ESS) located in the first exon. RT-PCR data indicates an 
accumulation of pre-mRNA and low level of mRNA (Figure 4.4A). The sequence of the 
first exon was scanned using SpliceAid2, a database of human splicing factors and 
RNA target motifs. The program predicted the sequence AAGAAGGGC as a putative 
binding motif for heterogeneous nuclear ribonucleoprotein (hnRNP) H1, H2, H3 and F 
known as ESS 107. The proposed ESS motif was mutated (SP_cr4-6, Figure 4.4B). All 
constructs exhibit significantly higher GFP expression, both at the OFF and ON state, 
but a decrease in the dynamic range compared to SP_cr (Figure 4.4C). Additionally, 
the construct SP_cr7 was cloned carrying an additional ESS motif. The GGAAGAAC 
motif was chosen that is recognized by the strong exonic splicing enhancer (ESE) 
SRSF1 108 (Serine/Arginine-rich splicing factor 1). Here the construct exhibits 2.5-fold 
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dynamic range while up to 100% intron is spliced in the present of dox (Figure 4.4C). 
However none of the constructs showed increased regulation. 
 
 
Figure 4.4 Mutated putative splicing motif. (A) Splicing pattern of SP, SP_cr and SP_cr6 constructs 
visualised by RT-PCR. Cells were transiently transfected with these constructs. Total RNA was prepared 
and used for RT-PCR with primer pairs binding to both exons. Upper bound corresponds to pre-mRNA 
and lower to mRNA. The spliced products were cloned using CloneJET PCR cloning kit and sequenced 
for verification. Experiment was repeated three times with similar results. (B) Using SpliceAid2, program 
predict the AAGAAGGGC sequence (green line) upstream 5SS, as a putative binding motif for exonic 
splicing silencers (ESS) like hnRNP H1, hnRNP H2, hnRNP H3 and hnRNP F. These ESS belong to 
the hnRNP family characterized as mediators of splicing silencing. Constructs SP_cr4-6 with mutated 
ESS motif were cloned. Additionally, a construct SP_cr7 that carries an exonic splicing enhancer motif 
(GGAAGAAC), recognized by strong splicing enhancer SRSF1, was cloned. Introduced mutations are 
marked in red and 5SS is shown in blue. An additional folding, upstream the aptamer structure, was 
detected by a RNA structure prediction programs (mfold). (C) Displayed are the GFP fluorescence for 
all constructs, values without (white bars) and with dox (black bars) and above each construct the 
regulatory activity are shown. Constructs were co-transfected with TetR:mCherry. GFP and mCherry 
expression was measured 24 h after transfection in the absence or presence of 50 µM dox with flow 
cytometry and mCherry expression was used to normalize for variation in transfection efficiency. 
Experiments were performed in triplicate and repeated three times with similar results. Error bars 
represent the standard deviation from the means. 
 
With the construct SP_cr used, 39 additional nucleotides remain after removal of the 
intron at the 5’ end of the open reading frame. This corresponds to 13 amino acids 
attached to the N-terminus of the protein of interest. This may not be tolerated by 
several proteins. The initial attempt to eliminate the additional nucleotides by moving 
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the start codon towards the 5SS (SP_cr8-10) was unsuccessful. Truncation of the exon 
to 12 nucleotides (SP_cr11) also showed negative results (Figure 4.5). 
 
 
Figure 4.5 Reduction of the aptamer-born amino acids. (A) Scheme of cr_5ss modifications. SP_cr8-
10 are constructs with shifted ATG position at the end of exon 1. For constructs SP_cr9 and SP_cr10 
additional mutations were inserted within first exon to introduce Kozak sequence to enhance translation. 
Introduced mutations are marked in red, 5SS is shown in blue and ATG start codon in green. Construct 
SP_cr11 has truncated first exon to 12 nt. In the construct SP_cr12, an additional ATG in the first exon 
that is out of frame was mutated (U9C, positions relative to the ATG start codon) to keep only one codon 
start. The porcine teschovirus-1 2A (P2A) peptide was introduced into SP_cr12, generating SP*. (B) 
Displayed are the GFP fluorescence for all constructs, values without (white bars) and with dox (black 
bars) and above each construct the regulatory activity are shown. Constructs were co-transfected with 
TetR:mCherry. GFP and mCherry expression was measured 24 h after transfection in the absence or 
presence of 50 µM dox with flow cytometry and mCherry expression was used to normalize for variation 
in transfection efficiency. Experiments were performed in triplicate and repeated three times with similar 
results. Error bars represent the standard deviation from the means. 
 
 
Additionally, a start codon located in the first exon was removed, resulting in an 
improvement to 8.8-fold (SP_cr12). Finally, we inserted a ‘self-cleaving’ peptide 
between the device and the start codon to remove the additional exon-born amino 
acids (construct SP*). The porcine teschovirus-1 2A (P2A) peptide was used with the 
sequence GSGATNFSLLKQAGDVEENPGP. The cleavage site of the peptide is 
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located between its last two amino acids 109, 110. Consequently, only one proline is 
added to the N-terminus of the protein of interest. It is expected that the majority of 
proteins will tolerate this minimal invasive change in their protein sequence. The 
addition of P2A domain slightly decreased the gfp expression, but increased the 
dynamic range to 9.2-fold (Figure 4.5B).  
Next, SP* as the best construct was chosen as TSD_GFP. The sequence of the 
complete device (292 nt) that can be transferred upstream of the coding sequence of 
any gene of interest is given in Figure 4.6. Further, a careful characterization of 
TSD_GFP was carried out. The switching capability at the mRNA level was analysed 
(Figure 4.6B). Intron retention was visualized by RT PCR using oligonucleotides 
binding to exon 1 and 2 and quantified by qPCR. In addition, the protein level was 
detected by western blot (Figure 4.6C). The qPCR data are consistent with GFP 
expression measured by flow cytometry (Figure 4.1.5B) supported by the Western blot 
experiment. Additionally, TSD_GFP was stably integrated using the HF1-3 Flp-In 
system. Stably integrated TSD_GFP shows the same regulation as in the transient 
situation (Figure 4.6D). Moreover, it was shown that TSD_GFP was functional in 
HEK293, HeLa, A549 and CHO cell lines [data not shown]. 
Finally, portability of the TSD in the context of other reporter gene mCherry and the 
human transcription factor MAX was assessed. Analogue as in the GFP context, the 
TSD was inserted at the 5’ end of the coding sequence of both genes, generating 
TSD_mCherry and TSD_MAX-GFP, respectively. The constructs were co-transfected 
with the plasmid expressing TetR. mCherry and MAX-GFP expression were measured 
24 h after transfection in the absence or presence of 50 µM dox using flow cytometry. 
In the case of mCherry control TSD was first inserted in front of mCherry, generating 
TSD_mCherry-1. This construct exhibits only ~1.6 regulation fold (Figure 4.7A). In the 
absence of dox the construct shows high mCherry expression. To check if the TetR 
aptamer can control intron retention event, RT-PCR was perform. The RT-PCR clearly 
shows that TetR aptamer leads to intron retention in the absence of dox (Figure 4.7B), 
and mCherry expression should be reduced at OFF state as mRNA transcript 
produced in the case of intron retention state contain introduced premature stop codon. 
This transcript should be degraded by a nonsense-mediated mRNA decay pathway.  
 
  Results   
[31] 
 
 
Figure 4.6 Validation of TSD. (A) General sketch of the TSD design. The TSD element is highlighted 
by a dotted line inserted in front of a gene of interest (GOI). Exons are displayed as boxes and the intron 
as a line, the self-cleaving domain P2A is displayed as a blue box. (B) Splicing pattern of P2A_GFP 
(control without the aptamer) and TSD_GFP (before SP*) constructs visualised by RT-PCR. Cells were 
transiently co-transfected with these constructs and with plasmid expressing TetR and treated with (+) 
or without (-) 50 µM dox for 24h. Total RNA was prepared and used for RT-PCR with primer pairs binding 
to both exons. Upper bound corresponds to a pre-mRNA and lower to mRNA. Quantification of % spliced 
was determined by qPCR analysis. (C) The protein expression of P2A_GFP and TSD_GFP constructs 
was analysed by Western blot analysis. Anti-GFP was used for GFP expression and anti-Actin was used 
as a loading control. Mock was transfected with TetR::mCherry and GFP+ is GFP control without P2A 
domain. Experiments were repeated three times with similar results. (D) Additionally, P2A_GFP and 
TSD_GFP constructs were stably integrated into HF1-3 cell line with Flp-In system. Generated cell lines 
expressing these construct were subsequently transiently transfected with TetR::mCherry and treated 
with or without 50 µM dox for 72h. The histogram for TSD_GFP with the regulatory activity is shown. 
GFP and mCherry was excited using a 488 nm laser with a 550/30 filter and 561 nm laser with a 610/20 
filter, respectively. Populations were selected by gating out the GFP background signal of untransfected 
cells with TetR::mCherry by FlowJo software. (E) The TSD sequence. Colour coding: exon sequences 
highlighted in grey, TetR aptamer inside the intron in yellow and P2A self-cleavage sequence in blue. 
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Therefore, another AUG is potentially use by ribosome which leads to correct mCherry 
production. The switching module may mimic upstream ORF (uORF) due to the short 
sequence, and another AUG in frame within mCherry sequence may be used. Several 
described mechanisms enable expression of the downstream ORF despite the 
presence of an uORF. Ribosomes may bypass the uAUG codon. The context of 
surrounding nucleotides is one determinant of AUG codon recognition by the ribosome. 
However, many uAUG codons do not have the optimal sequence, leading to the 
prediction that some scanning ribosomes are likely to bypass them, a process known 
as ‘leaky scanning’. Even if the ribosome recognizes an uAUG codon and translates 
the uORF, it might reinitiate at a downstream AUG codon 111, 112, 113. At the beginning 
of mCherry sequence the AUG codon in frame (it is 24 nt after TSD) is present, that 
may produce an active mCherry. To test if another AUG can be used by ribosome, a 
construct TSD_mCherry with mutated 26G to 26A within mCherry sequence was 
cloned. The TSD_mCherry construct exhibits ~10-fold regulation (Figure 4.7A) 
demonstrating that TSD can control mCherry gene and that ‘leaky mechanism’ may 
have happened. Therefore, it will be necessary to scan a sequence of GOI for a 
presence of putative AUG codons and mutate them. 
While, the MAX gene was fused with GFP as a reporter at its C-terminus to allow 
detection of MAX protein expression by flow cytometry. MAX-GFP construct exhibits a 
5.4-fold regulation (Figure 4.7C). The dynamic range of MAX-GFP was slightly lower 
compared to the TSD_GFP or TSD_mCherry constructs possibly due to the fusion of 
MAX with GFP.   
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Figure 4.7 TSD portability. (A) TSD controlling mCherry expression. TSD_mCherry-1 and 
TSD_mCherry constructs carry TSD placed in front of mCherry coding sequence. Additionally, 
TSD_mCherry has mutated 26G to 26A within mCherry sequence. Control gene has inserted coding 
sequence from TSD (without TetR-intron sequence). Constructs were co-transfected with TetR. 
mCherry expression was measured 24 h after transfection in the absence or presence of 50 µM dox 
with flow cytometry. Displayed are the mCherry fluorescence values without (white bars) and with dox 
(black bars) and above each construct the regulatory activity are shown. (B) Splicing pattern of 
TSD_mCHerry-1 construct visualised by RT-PCR. Cells were transiently co-transfected with this 
construct and with plasmid expressing TetR and treated with (+) or without (-) 50 µM dox for 24h. Total 
RNA was prepared and used for RT-PCR with primer pairs binding to both exons. Upper bound 
corresponds to a pre-mRNA and lower to mRNA. (C) TSD in the context of MAX transcription factor. 
MAX was additionally fused with GFP as a reporter at its C-terminus to allow detection of MAX 
expression by flow cytometry. Constructs were co-transfected with the mCherry tagged TetR. mCherry 
and GFP expression was measured 24 h after transfection in the absence or presence of 50 µM dox. 
Displayed are the GFP fluorescence values without (white bars) and with dox (black bars) and the 
regulatory activity above each construct are shown. (A and C) Experiments were performed in triplicate 
and repeated three times with similar results. Error bars represent the standard deviation from the 
means.   
 
In summary, these results clearly demonstrate that TSD was able to control the 
expression of several genes of interest, with splicing regulation directly translating into 
protein output which additionally highlights the genetic modularity and robustness of 
the device. 
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4.2 Project II: Inducible control of nuclear import using TetR aptamer 
The nucleo-cytoplasmic transport is essential for cell physiology and aberrant 
spatiotemporal localization of proteins leads to various forms of cancer or other 
diseases 114, 115. The manipulation of protein localisation by targeting the protein 
folding, signal transduction and nuclear transport would provide a promising antiviral 
and anticancer strategy 116. However, despite the importance of this process, this has 
not yet been extensively explored. Currently, few inhibitors have been identified to 
interfere with the nuclear transport 117, 118. Therefore, development of synthetic devices 
that allow spatial regulation of gene expression would be valuable in phenotypic 
studies of essential genes and therapeutic strategies that target protein localization 116, 
119. Controlling nuclear localisation as a strategy to control protein activity can be 
accomplished at the mRNA or protein level. Previously, two tools were engineered for 
mRNA transport, however, these systems are only capable of cytoplasmic 
redistribution of mRNA in the cells, one of which is limited to yeast 120, 121. Other devices 
able to control mRNA shuttling between cytoplasm and nucleus in human cells have 
not been demonstrated. All existing tools controls protein activity at the level of protein 
localisation, which are based on chemical 120, 122, 123, 124 or light-inducible systems 119, 
125, 126. In the second part of the thesis we created the first inducible model for 
alternative 3’ splice site (A3SS) recognition with the TetR aptamer that leads to 
production of splice variants with different subcellular localization. The practicality of 
the system was further shown by controlling nuclear import in human cells, which may 
provide an alternative for therapeutic strategies. 
 
4.2.1 Results 
As a first step toward creating a device for the control of A3SS using the TetR aptamer 
system, the MINX intron with flanking exon sequences was placed in front of an egfp 
reporter gene. This small intron derives from the adenovirus and is efficiently spliced 
in human cells 127 (Figure 4.8). Next, the TetR aptamer was placed upstream of the 
canonical 3SS (Figure 4.9A). The TetR aptamer contains five potential sequences that 
can be recognized as A3SS (A3SS-T1). In the first step, two CAGs in the aptamer loop 
were mutated (A3SS-T2; Figure 4.9B). The AAG should not be used as 3SS as it is a 
weak splice site compared to the upstream CAGs. GAG is generally not used as a 3SS 
in eukaryotic cells with few exceptions 128.  
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Figure 4.8 MINX intron. (A) sequence of used MINX intron. Flanking exons are marked in grey. Start 
ATG codon, branch point adenosine and AG are in bold and the Py-tract is highlighted. Introduced KpnI 
restriction site is in italic. Position of aptamer insertion indicated by *. (B) Splicing pattern of control 
MINX-EGFP construct visualised by RT-PCR. HeLa cells were transiently transfected with the MINX-
EGFP, transfected with plasmid expressing TetR (+) and treated with (+) or without (-) 50 µM dox for 
24h. Total RNA was prepared and used for RT-PCR with primer pairs binding to both exons. The bound 
corresponds to spliced product. Experiment was repeated three times with similar results. 
 
HeLa cells were transiently transfected with these constructs together with a plasmid 
expressing TetR and treated with or without 50 µM dox for twenty-four hours. TetR 
itself was expressed by a strong CMV promoter and modified at its N-terminus with a 
nuclear localization signal (NLS) from c-MYC that significantly increased its localization 
in the nucleus. Splicing pattern was visualized by RT-PCR using primer pairs binding 
to both exons. In both constructs spliceosome recognized only the first A3SS in the 
aptamer and the distal 3SS (Figure 4.9B). Interestingly, for A3SS-T1 construct 
enhanced A3SS usage in the present of TetR is observed.  
Next, based on A3SS-T1 construct, the aptamer stem length and composition (A3SS-
T3-T7; Figure 4.10), as well as the polypyrimidine(Py)-tract length and position relative 
to the aptamer was characterized and optimized (A3SS-T8-T13; Figure 4.11). The 
short aptamer stem in A3SS-T3, as well as more pyrimidines upstream the A3SS in 
A3SS-T5 leads to the exclusive recognition of the A3SS. The aptamer stem 
stabilization by additional G-C base pairing in A3SS-T6 enhanced switching behaviour 
most prominently in the presents of dox, as compared to A3SS-T1. Also, the Py-tract 
position and its composition relative to the aptamer and distal AG has a strong 
influence on the splicing pattern. The mutations of pyrimidines upstream the stem in 
A3SS-T9 decreased the splicing efficiency. Interestingly, the presence of TetR still 
increases the A3SS recognition. Increased Py-tract downstream the aptamer leads to 
the recognition by spliceosome only of the distal 3SS and the A3SS is sequestered in 
the stem. However, the aptamer distance relative to the 3SS seems to be important for 
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switching properties. Recognition of A3SS in the presence of TetR is diminished with 
increasing distance between the aptamer and distal AG, which is observed in the 
constructs A3SS-T11, A3SS-T12 and A3SS-T13. Based on these results, the A3SS-
T11 was selected as the constructs with the most desirable properties. In this construct, 
in the absence of TetR spliceosome recognizes exclusively the distal AG and the A3SS 
is sequestered in the aptamer stem. However, the presence of TetR activates the 
A3SS recognition. Again the A3SS can be switched off by addition of dox. 
 
 
Figure 4.9 TetR aptamer placed at 3SS. (A) TetR aptamer with A3SS is placed upstream the canonical 
3SS of MINX intron. (left) In absence of TetR, distal AG is recognized by spliceosome. (middle) In the 
presence of TetR, A3SS is recognized. (right) Splicing pattern can be restored by addition of dox that 
leads to conformational changes of TetR and the release of the aptamer. Selected 3SS is marked in 
red. Exons are displayed as boxes and intron with TetR aptamer as a line. (B) Schemas of the TetR 
aptamer structure at the 3’ intron end of A3SS-T1 and A3SS-T2 construct. Used alternative A3SS and 
distal AG are marked in red. In the aptamer stem other alternative AGs are marked. Splicing pattern 
visualised by RT-PCR. HeLa cells were transiently transfected with the constructs A3SS-T1 and A3SS-
T2 and co-transfected with plasmid expressing TetR (+) and treated with (+) or without (-) 50 µM dox for 
24h. Total RNA was prepared and used for RT-PCR with primer pairs binding to both exons. Upper 
bound corresponds to usage of A3SS and lower to distal AG. The spliced products were cloned using 
CloneJET PCR cloning kit (Thermo Scientific) and sequenced for verification. Experiment was repeated 
three times with similar results. 
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Figure 4.10 The aptamer stem modification. Schemas of the TetR aptamer structure at the 3’ intron 
end of A3SS-T3-T7 constructs. Used alternative A3SS and distal AG are marked in red. Splicing pattern 
visualised by RT-PCR. HeLa cells were transiently transfected with these constructs and co-transfected 
with plasmid expressing TetR (+) and treated with (+) or without (-) 50 µM dox for 24h. Upper bound 
corresponds to usage of A3SS and lower to distal AG. Experiment was repeated three times with similar 
results. 
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Figure 4.11 The Py-tract characterization. Schemas of the TetR aptamer structure at the 3’ intron end 
of A3SS-T8-T13 constructs relative to the Py-tract position and composition. Used alternative A3SS and 
distal AG are marked in red. Splicing pattern visualised by RT-PCR. HeLa cells were transiently 
transfected with these constructs and co-transfected with plasmid expressing TetR (+) and treated with 
(+) or without (-) 50 µM dox for 24h. Upper bound corresponds to usage of A3SS and lower to distal AG. 
Experiment was repeated three times with similar results. 
 
Introduced mutations that destroys the TetR binding leads to a complete loss of A3SS 
regulation, indicating that switching is indeed mediated by TetR aptamer interaction 
(A3SS-T11*, Figure 4.12). Moreover, mutated A3SS in A3SS-T11 leads to exclusive 
usage of another A3SS* (A3SS-T14, Figure 4.12) in the aptamer and loss of switching 
behaviour. Additionally, lariat PCR to detect branch point (BP) sequence for both splice 
variants was performed. In absence of TetR the BP was predicted to be at adenosine 
(A) in the window of 42 nt upstream the distal AG. It is relative distance, where the 
stem length is not counted in to the final distance and the stem keeps 3SS closer to 
  Results   
[40] 
 
the BP 128. While, in the presence of TetR the BP was predicted to be at the same A in 
the window of 42 nt to A3SS.  
 
 
Figure 4.12 Mutated TetR binding site and the stem stabilization in A3SS-T11 and lariat PCR. (A) 
Schemas of the A3SS-T11* and A3SS-T14 constructs with mutated TetR binding site and the stabilized 
stem, based on A3SS-T11, respectively. Used alternative A3SS or A3SS* and distal AG are marked in 
red. Splicing pattern visualised by RT-PCR. HeLa cells were transiently transfected with these 
constructs and co-transfected with plasmid expressing TetR (+) and treated with (+) or without (-) 50 µM 
dox for 24h. Upper bound corresponds to usage of A3SS and lower to distal AG. The spliced products 
were cloned using CloneJET PCR cloning kit and sequenced for verification. Experiment was repeated 
three times with similar results. (B) Schema of lariat PCR design for A3SS-T11 construct. Alternative 
A3SS and distal AG are marked in red, and 5SS and BP are marked in blue and yellow, respectively. 
The lariat PCR products were sequenced for verification and the sequencing chromatogram is depicted. 
(C) Splicing pattern visualised by RT-PCR and schema of detected BP positions. The triangles indicated 
detected putative BP in the presence of TetR (+) or in its absence (-). The predicted BP for MINX without 
the aptamer is marked as *. Human BP consensus is shown 129. Additionally, the relative distance 
between predicted BP (A in red) and A3SS or distal AG is presented.     
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Following an existing alternative splicing mechanism for modulating the cell cycle-
regulated Nek2 kinase localisation 130, that enables it to have both cytoplasmic and 
nuclear functions, we designed a device (A3SS-TN) for controlling nuclear import. 
Taking advantage of the control of alternative splicing in A3SS-T11 it is possible to 
produce two splice variants. The aptamer P2 stem can be tailored according to various 
required modifications while preserving its structure, specifically, the binding region. 
This allows for insertion of a nuclear localisation sequence (NLS) between the A3SS 
and AG. Which further would leads to production of different splice variants with 
different subcellular localisation on demand (Figure 4.13).  
 
 
Figure 4.13 Schema of the proposed model to control nuclear import. In absence of TetR, distal 
AG is recognized by spliceosome. In the presence of TetR the A3SS is activated and furthermore, 
splicing pattern can be restored by addition of dox that leads to conformational changes of TetR and 
releasing the aptamer. Insertion of nuclear localisation sequence (NLS, in blue) between A3SS and AG 
allows to produce different splice variants with different subcellular localisation on demand. Exons are 
displayed as boxes and intron with TetR aptamer as a line.  
 
First, it was assessed if the introduction of a NLS sequence between the A3SS and 
3SS in A3SS-T11 would disrupt the switching properties (Figure 4.14). If consequently 
could lead to the production of different splice variants with and without NLS. To 
maintain NLS and EGFP in the open reading frame the stem length or distance 
between the aptamer and 3SS (A3SS-TN1, A3SS-TN2 and A3SS-TN3) was adjust. 
For these constructs slight splicing pattern changes were observed, however, A3SS-
TN2 exhibits desired properties to produce two splice variants in the present of TetR. 
Interestingly, in these constructs also the ability to activated A3SS in the present of 
TetR was observed, due to the distance between the aptamer and distal AG. 
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Figure 4.14  Insertion of NLS sequence within the TetR aptamer. Schemas of the A3SS-TN1 and 
A3SS-TN2 constructs with added NLS sequence (in blue) on top of the TetR aptamer. Alternative A3SS 
and distal AG are marked in red. Splicing pattern visualised by RT-PCR. HeLa cells were transiently 
transfected with the constructs A3SS-T1 and A3SS-T2 and co-transfected with plasmid expressing TetR 
(+) and treated with (+) or without (-) 50 µM dox for 24h. Total RNA was prepared and used for RT-PCR 
with primer pairs binding to both exons. Upper bound corresponds to usage of A3SS and lower to distal 
AG. The spliced products were cloned using CloneJET PCR cloning kit (Thermo Scientific) and 
sequenced for verification. Experiments were performed in triplicate and repeated three times with 
similar results. 
 
Further, it was examined if the control on mRNA levels can be translated into protein 
level. For this purpose, A3SS-TN2 was fused with the cytosolic protein (CP) in order 
to prevent passive EGFP diffusion into the nucleus resulting in A3SS-TN2-CP 
construct. To reduce background of untransfected cells, A3SS-TN2-CP as well as 
EGPF control were stably integrated into a HeLa HF1-3 cell line using the Flp-In 
system. A generated cell line expressing the A3SS-TN2-CP was subsequently 
transiently transfected with TetR::mCherry construct that can be visualized by 
fluorescence microscopy. After transfection with a plasmid expressing TetR and 
treated with or without 50 µM dox for 24 or 48 h, cells where fixed and stained with 
DAPI. The microscopic images of EGFP show a homogenous distribution throughout 
the cell, however with a tendency to accumulate in the nucleus due to passive diffusion, 
while expressed TetR tagged with mCherry was primarily localized in the nucleus 
(Figure 4.15).  
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Figure 4.15 Microscopic visualisation of EGFP and TetR::mCherry controls. EGFP is stably 
integrated into HF1-3 cell line using the Flp-In system and transiently transfected Hela cells with the 
mCherry-tagged TetR. Cells where fixed and stained with DAPI. Scale bar 10 µm. 
 
Constitutively expressed A3SS-TN2-CP show predominant cytoplasm localization 
(Figure 4.16A). It confirms that only distal the 3SS is used, producing an isoform 
without NLS. In the present of TetR, in most cells EGFP is expressed in the cytosol as 
well as it is accumulated in the nucleus and nucleoli. It indicates that the A3SS is 
activated in the presents of TetR and the second splice variant carrying NLS is 
produced (Figure 4.16B). Additionally, cells expressing TetR and incubated with dox 
show mostly cytoplasm distribution, meaning that dox leads to the release of TetR from 
the pre-mRNA (Figure 4.16C).  
 
Figure 4.16 Microscopic visualisation of inducible control of nuclear import with TetR aptamer. 
(A) A3SS-TN2-CP stably integrated into HeLa HF1-3 cell line using the Flp-In system. (B-C) A generated 
cell line expressing A3SS-TN2-CP construct was transiently transfected with mCherry-tagged TetR (+) 
and treated with (+) or without (-) 50 µM dox for 24h. Cells where fixed and stained with DAPI. Scale 
bar 10 µm. 
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In sum, with the TetR aptamer complex it is possible to switch on A3SS on demand 
and moreover produce two functional splice variants with different cytosol and nuclear 
distribution. After 48 h most cells expressing A3SS-TN-2-CP and TetR show 
homogenous distribution of EGFP in the nucleus (Figure 4.17).  
 
 
Figure 4.17 Microscopic visualisation of inducible control of nuclear import with TetR aptamer. 
A generated cell line expressing the A3SS-TN2-CP was transiently transfected with mCherry-tagged 
TetR construct and incubated 24h (upper panel) or 48h (lower panel). White triangles indicate the cells 
with observed EGFP accumulation in the nucleoli. Cells where fixed and stained with DAPI. Scale bar 
25 µm (upper panel)  and 10 µm (lower panel). 
 
Additionally, it was assessed whether it is possible to produce two splice variants with 
mitochondrial or nuclear distribution. For this purpose, it was verified if a EGFP with a 
strong mitochondrial localization signal (MLS) from Cytochrome C Oxidase Subunit 8A 
(COX8A) will localize in mitochondria and if EGFP with both targeting signals, NLS and 
MLS is able to accumulate in the nucleus. Control expressing MLS-EGFP and NLS-
MLS-EGFP were transiently transfected in HeLa cells. The microscopic images of the 
MLS-EGFP show a mitochondrial distribution and NLS_MLS_EGFP was primarily 
localized in the nucleus (Figure 4.18). 
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Figure 4.18 Microscopic visualisation of MLS-EGFP and NLS-MLS-EGFP controls. (Upper panel) 
Mitochondrial staining reagent was used to label mitochondria of HeLa cells (Mito Tracker, Abcam). 
Transiently transfected Hela cells with MLS-EGFP (middle panel) and NLS-MLS-EGFP (lower panel). 
Cells where fixed and stained with DAPI. Scale bar 10 µm. 
 
Further, A3SS-TN2 was fused to the MLS resulting in the A3SS-TN2-MLS construct, 
that was stably integrated into HeLa HF1-3 cell line using the Flp-In system, to reduce 
background of untransfected cells. A generated cell line expressing the A3SS-TN2-
MLS construct was subsequently transiently transfected with the mCherry-tagged 
TetR. After transfection with a plasmid expressing TetR and treated with or without 50 
µM dox for 24 h cells where fixed and stained with DAPI (Figure 4.19). Constitutively 
expressed A3SS-TN2-MLS show predominant mitochondrial localization (Figure 
4.19A). It confirms that only the distal 3SS is used, producing an isoform without NLS. 
However, in the present of TetR only mitochondrial EGFP distribution is observed and 
the nuclear localization is not detected. The same EGFP pattern is observed in the 
cells expressing TetR and incubated with dox (Figure 4.19B-C).  
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Figure 4.19 Microscopic visualisation of inducible control of nuclear import with TetR aptamer. 
(A) A3SS-TN2-CP stably integrated into HeLa HF1-3 cell line using the Flp-In system. (B-C) Generated 
cell line expressing A3SS-TN2-CP construct was transiently transfected with mCherry-tagged TetR (+) 
and treated with (+) or without (-) 50 µM dox for 24h. Cells where fixed and stained with DAPI. Scale 
bar 10 µm. 
 
In a cooperation with the Cancer Metabolism research group, headed by Dr. Dimitrios 
Anastasiou at the Francis Crick in London we will test the model to investigate the 
function of GLS isoforms. This gene encodes the K-type mitochondrial glutaminase. 
Glutamine is an essential nutrient for cancer cell proliferation, especially in the context 
of citric acid cycle anaplerosis. Recent studies have shown the importance of 
glutaminolysis in maintaining the malignant phenotype, providing indications that 
glutaminases may be a potential therapeutic targets in some cancer cells 131. The idea 
is to control the formation of the two splice variants of GLS with cytosolic and 
mitochondrial localization to assess the function of both isoforms in the glycolytic 
pathway. For this purpose, the aptamer stem will be replaced by the native MLS form 
GLS. While, instead of egfp is placed GLS. First, the predicted MLS sequence from 
GLS was tested if it has mitochondrial targeting properties. The fusion of the MLS 
(Table 6.1) to EGFP shows predominant mitochondrial localization in HeLa cells 
(Figure 4.20). Next, we designed and cloned constructs with MLS placed within the 
aptamer, like in the case of A3SS-TN2. These constructs were stably integrated and 
are currently tested in the Anastasiou’s research group. 
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Figure 4.20 Control of GLS splice variants. (upper panel) Schema of the proposed model to control 
mitochondrial import. In absence of TetR, distal AG is recognized by spliceosome. In the presence of 
TetR the A3SS is activated and furthermore, splicing pattern can be restored by addition of dox that 
leads to conformational changes of TetR and the release of the aptamer. Insertion of mitochondrial 
localisation sequence (MLS, in blue) between A3SS and AG allows to produce different splice variants 
of GLS with different subcellular localisation on demand. Exons are displayed as boxes and intron with 
TetR aptamer as a line. (middle panel) Microscopic visualisation of transiently transfected HeLa cells 
with MLS-GLS-EGFP construct carrying the predicted MLS form GLS. Cells where fixed and stained 
with DAPI. Scale bar 10 µm. (lower panel) Schemas of the A3SS-TM1 and A3SS-TM2 constructs with 
added MLS sequence (nucleotides in blue) on the top of TetR aptamer. Alternative A3SS and distal AG 
are marked in red. 
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4.3 Project III: Control of mammalian translation with TetR aptamer  
Translational regulation constitutes an important point of post-transcriptional control of 
gene expression, enabling the cell to change the level of gene product rapidly. 
Translation is mainly regulated at the step of initiation 132. In eukaryotes, the 43S 
preinitiation complex is recruited at the 5’ cap and scans the entire 5’ untranslated 
region (UTR) in search for a start codon. The presence of secondary structure 
elements such as stem-loops or hairpins in the 5’ UTR negatively affects translation 
initiation 133. The potency of inhibition is dependent on the stability and the position of 
the structured elements in the 5’ UTR. Insertion of aptamers downstream of the 5’ cap 
and in front of the start codon can block ribosome scanning and translation of the 
downstream gene 134, 135, 136. However, translational control differs in yeast and 
mammalian cells and this mechanism appears to only work in yeast, while the 
mammalian ribosome is able to efficiently scan through structured RNAs before the 
start codon 19, 137. In this project, TetR aptamer dependent translational control system 
was developed and optimized in mammalian cells.  
 
4.3.1 Results 
The TetR aptamer was placed within the 5’ UTR of the egfp reporter gene in a way that 
TetR binding to the aptamer efficiently inhibits ribosomal scanning. The translation start 
codon AUG is localized in the aptamer (Figure 4.21). Additionally, a 2A ‘self-cleaving’ 
peptide from the porcine teschovirus-1 2A (P2A) was attached upstream of the egfp to 
remove additional aptamer-born amino acids. P2A peptide results into one additional 
amino acid added to the protein of interest and it is expected that the majority of 
proteins may tolerate this minimal change of their protein sequence. TetR binding to 
the aptamer stabilizes its secondary structure which leads to inhibition of the ribosome 
scanning and consequently the inhibition of translation (OFF state) of the controlled 
gene. Addition of dox then releases TetR from the aptamer resulting in correct 
translation (ON state; Figure 4.23).  
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Figure 4.21 Translation control with TetR aptamer. TetR aptamer within an 5’ untranslated region 
(UTR) of the egfp reporter gene. The start codon is marked in red and self-cleaving domain (p2a) in blue 
(A) In the presence of TetR, ribosome scanning is blocked and consequently no translation of the 
controlled gene takes place. (B) Translation can be restored by addition of dox that leads to 
conformational changes of TetR and the release of the aptamer.  
 
To assess whether the TetR aptamer is able to control translation in HeLa cells, 
constructs T1, T2 and T3 (Figure 4.22A) were designed. The aptamer sequence 
contains two start codons, therefore one of them was mutated (T1 and T2). In addition 
the aptamer stem was stabilized by CG base pairs in T2 construct.  
 
 
Figure 4.22 Assessing the control of translation with TetR aptamer. (A) Schemes of the T1-T3 
constructs. The start codon is marked in blue and mutated nucleotides in red. A possible additional 
binding of 3 base pairs (in grey) of the BamHI restriction site with the P2A sequence was predicted with 
mfold program. Additional stem formation was included in the final ΔG prediction. The ΔG in kcal/mol of 
the constructs is displayed in brackets (B) Displayed are the EGFP fluorescence for all constructs, 
values without (white bars) and with dox (black bars) and above each construct the regulatory activity 
are shown. Constructs were co-transfected with TetR:mCherry. EGFP and mCherry expression was 
measured 24 h after transfection in the absence or presence of 50 µM dox with flow cytometry and 
mCherry expression was used to normalize for variation in transfection efficiency. EGFP* is a control 
without the aptamer. Experiments were performed in triplicate and repeated three times with similar 
results. Error bars represent the standard deviation from the means. 
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Cells were transiently transfected with these constructs together with a plasmid 
expressing TetR tagged with mCherry. EGFP and mCherry expression were monitored 
24 h after transfection in the absence or presence of dox using flow cytometry. mCherry 
expression was used to normalize for variation in transfection efficiency. Construct T2 
exhibits the best regulatory properties with a 6.8-fold (Figure 4.22B) and was chosen 
for further optimizations. Additionally, the introduction of the two mutations that destroy 
TetR binding (T2*) leads to a complete loss of regulation indicating that switching is 
indeed mediated by TetR aptamer interaction. 
 
Furthermore, it was assessed whether and to what extent the stability of the aptamer 
influences regulation. Based on T2, a set of constructs T4-T31 was designed, mainly 
modifying the aptamer stem (Figure 4.23A) and the hairpin loop (Figure 4.23B). The 
aptamer stem was destabilized by stem truncations, exchanging a CG for weaker AU 
or GA base pairs, the insertion of an adenine bulges or an AG mismatch. While, 
insertion of additional CG base pairs lead to stem stabilization, the hairpin loop was 
exchanged by more stable tetraloops. The aptamer structures were designed with 
predicted stabilities between -14 and -42 kcal/mol. The ΔG (kcal/mol) was calculated 
for the whole aptamer sequence using the mfold program. 
Only T6 and T19 of all tested constructs show improved regulation (8.5-fold). 
Interestingly, the removal of the three base pairs in the closing stem of the aptamer 
results in an increased egfp expression in the presence of dox with a maintained low 
basal expression level in the repressed state. All constructs with the destabilized 
aptamer stem exhibit higher egfp expression with or without dox, in contrast to the 
construct with the stabilized aptamer stem. An too weak the aptamer stem is 
associated with the loss of translational control by TetR. Moreover, the stabilization of 
hairpin loops leads to decreased egfp expression in both states but neither of them 
showed increased regulation (Figure 4.23B).  
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Figure 4.23 T2 optimization. (A) Schemes of the T4-T27 constructs with modified aptamer stem and 
corresponding egfp expressions. Deleted nucleotides are marked in light grey and in red introduced 
mutations. The triangles indicate constructs with improved fold (T6 and T19). (B) Schemes of the T28-
T31 constructs with modified aptamer closing loop and corresponding egfp expressions. The start codon 
is marked in blue. (A-B) Values without (white bars) and with dox (black bars) and above each construct 
the regulatory activity are shown. The T2* expression was set as 100%. Constructs were co-transfected 
with TetR:mCherry. EGFP and mCherry expression was measured 24 h after transfection in the absence 
or presence of 50 µM dox with flow cytometry. mCherry expression was used to normalize for variation 
in transfection efficiency. Experiments were performed in triplicate and repeated three times with similar 
results. Error bars represent the standard deviation from the means. 
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It is known that the extent of inhibition is a function of the stability and position of the 
structured element in the 5’ UTR 133. To study the position and structure dependence 
of the aptamer-mediated regulation, the aptamer was placed directly behind the cap 
site (T32; Figure 4.24A). The cap-proximal aptamer structure is highly inhibitory (Figure 
4.24D), even in the absence of TetR. Although, the translation regulation is observed 
with the aptamer but with no improved regulation. 
Next, was assessed whether the presence of short uORF (upstream open reading 
frame) can influence and increase the regulation of translation of the main ORF with 
the aptamer. Construct T33 contains a stop codon downstream the aptamer, and a 
second start codon placed upstream of the egfp, generating an uORF (Figure 4.24B). 
However, the presence of the uORF in this construct has only a modest effect on the 
translation regulation of main ORF (Figure 4.24D).  
In yeast, it has been demonstrated 138 that a ligand inhibition of mRNA translation is 
most efficient when multiple binding sites are present in the 5’ UTR. Therefore, effect 
of tandem aptamer on the dynamic range in HeLa cells was studied. TT1-TT3 
constructs were designed with two and TT4 with three aptamers within 5’ UTR (Figure 
4.24C). Additionally, in TT2 a second start codon in the aptamer was shifted out of the 
ORF. TT1 and TT2 have the cap-distal aptamers positioned, while TT3 contains the 
aptamers at both 5’ UTR ends. In the case of TT4 construct the aptamers are cap-
proximal, middle and distal located. The use of two aptamers in TT1 and TT2 slightly 
reduced the egfp expression as well as the regulation (Figure 4.24D). However, the 
cap-proximal and -distal aptamer positions in TT3 led to an increased egfp expression 
in the presence of dox with maintained low basal expression level in the repressed 
state, consequently improving the regulation. Likewise, insertion of three aptamers 
within the 5’ UTR in TT4 shows improved regulation (11.2-fold).  
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Figure 4.24 Attempts to improve a translation regulation with the aptamer. Constructs with the (A) 
cap-distal or proximal aptamers location, (B) introduced upstream open reading frame (uORF) and (C) 
multiple TetR binding sites in the 5’ UTR of the egfp reporter gene. The start codon in the ORF is marked 
in red. (D) The EGFP fluorescence for all constructs, values without (white bars) and with dox (black 
bars) and above each construct the regulatory activity are shown. The T2* expression was set as 100%. 
Constructs were co-transfected with TetR:mCherry. EGFP and mCherry expression was measured 24 
h after transfection in the absence or presence of 50 µM dox with flow cytometry. mCherry expression 
was used to normalize for variation in transfection efficiency. Experiments were performed in triplicate 
and repeated three times with similar results. Error bars represent the standard deviation from the 
means. 
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Additionally, this system was tested together with the TetR aptamer splicing device 
from the first project to achieve a tighter control of gene expression. The aptamer from 
T2 construct was inserted into the 5’ UTR of SP*, generating T2-SP* constructs (Figure 
4.25). Dual control of egfp expression at the splicing and translation level provides 
increased regulation up to 14.7-fold of controlled gene, compared to an individual 
control (~7-8.5-fold).  
 
 
Figure 4.28 Dual control of a gene expression. (left) Schema of the T2-SP* construct with TetR 
aptamer inserted within the 5’ UTR and intron. Exons are displayed as boxes, 5’ UTR and intron with 
TetR aptamer as a line. The start codon in the ORF is marked in red. (right) The EGFP fluorescence for 
EGFP*, T2, SP* and T2-SP* constructs, values without (white bars) and with dox (black bars) and above 
each construct are shown the regulatory activity. The EGFP* expression was set as 100%. Constructs 
were co-transfected with TetR:mCherry. EGFP and mCherry expression was measured 24 h after 
transfection in the absence or presence of 50 µM dox with flow cytometry. mCherry expression was 
used to normalize for variation in transfection efficiency. Experiments were performed in triplicate and 
repeated three times with similar results. Error bars represent the standard deviation from the means. 
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5 Discussion 
5.1 Universal and efficient splicing device for controlling a gene expression in 
human cells.  
In the first project, a versatile and highly efficient TSD was designed to control gene 
expression with the TetR aptamer in human cells. It has been reported that the 5SS is 
recognized by base pairing to the 5’ end of U1. Previously, in our group inhibition of 
5SS by artificial tc aptamer has been shown in yeast 60. The tc aptamer is inserted in 
a way that the consensus sequence of 5SS was integrated within the closing stem of 
the aptamer and the 5SS in the presence of tc is blocked. Similar to this model, the 
TetR aptamer complex can conditionally block the U1 binding, which leads to intron 
retention. Reversible and robust control of 5SS recognition using TetR aptamer 
allowed us to establish the first intron retention switching module, named TSD, to 
control protein expression on the level of splicing. In addition, induction of TSD is 
achieved using inexpensive, cell permeable and not-toxic dox. The engineered switch 
shows a high dynamic range up to 10-fold and low basal activity that is a main 
challenge in mammalian synthetic biology. Additionally, TSD is an easily applicable 
device as it has only 292 nt, and a controlled protein of interest has only one added 
amino acid at the N-terminus. These characteristics represent a considerable 
improvement compared to existing RNA splicing regulators in human cells, which 
exhibits a low dynamic range up to 4-fold, are the size of ~1300 nt and are not 
reversible 61. In addition, TSD was functional in HEK293, HeLa, A549 and CHO cell 
lines, thus demonstrating its robustness, despite the fact that splicing is highly cell type-
specific. 
Modularity is an essential concept in engineering fields that can be applied to synthetic 
biology. However, engineered devices may not actually exhibit modular behaviour and 
often a device’s features may change under different conditions 106, 139, 140. Designing 
the TSD, an influence of surrounding genetic context of the aptamer on its switching 
behaviour was observed. First, a cryptic 5SS in the aptamer closing stem was 
responsible for low expression of both FLuc and GFP genes. RT-PCR analysis 
confirmed significant accumulation of pre-mRNA and low mRNA level for these 
constructs. Moreover, inhibition of intron removal was caused also due to the binding 
of strong exonic splicing silencers directly upstream the 5SS. Mutations in both cryptic 
5SS and predicted ESS motif significantly exhibit higher GFP expression. However, 
loss of the ESS motif is associated with the weakened regulation properties. Besides 
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this, a predicted small stem loop structure upstream the aptamer may contribute to the 
high switching regulation in SP* and additionally confirm the assumptions about the 
impact of splicing factors on the recognition of 5SS as often cis-elements are exposed 
in the loop stems 141. These studies allow for better understanding and will guide future 
design of artificial splicing systems for controlling gene expression.  
In sum, the proper functioning of the switching module was assessed in the context of 
different reporter genes like FLuc, GPF, and mCherry and the human transcription 
factor MAX. 
 
The system may also be applied to gain insight into diverse cellular mechanisms, such 
as pre-mRNA splicing, to study the impacts on cellular behaviour. We anticipated that 
the TSD can be used in a multi-gene context, where several genes are controlled by 
TSD and these genes are spaced by additional 2A sequences. Additionally, TSD can 
be easily combined with other regulatory systems to control gene expression at 
different levels to achieve tighter control of gene expression compared to either 
individual module, e.g. with a tetracycline aptamer controlled 3SS or aptazymes that 
impact mRNA stability.  
 
5.2 Control of an A3SS recognition with the TetR aptamer  
With the TetR aptamer complex it is possible to switch on an A3SS on demand and 
moreover produce two functional splice variants with a different cytosol and nuclear 
distribution. In the absence of TetR, the spliceosome recognized only the distal 3SS 
and the A3SS is sequestered in the stem in accordance with the model for 3SS 
recognition 128.  
The 3SS is encoded only by the dinucleotide AG, which is present in the genome very 
frequently. In mammalian genes the mechanism of 3SS selection is still poorly 
understood 142. The spliceosome is assisted in the 3SS identification by a Py-tract, a 
sequence located between the branch site and the dinucleotide AG 143. Most studies 
on the recognition of the 3SS site was done for yeast and are only little information for 
human cells. This is connected tied to the flexibility of 3SS, BP and Py-tract in 
mammalian introns. In yeast the BP sequence is highly conserved and early steps of 
splicing are independent of the 3SS. In mammalian splicing, independence of AG is 
related with the BP and Py-tract elements. The second step of splicing involves a 
mechanism in which the spliceosome scans the intron from the BP until the first AG is 
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encountered 91. Mutations in the dinucleotide AG in mammalian genes prevent 
cleavage at the 5SS and spliceosome complex formation. This suggests that the 3SS 
site selection likely occurs in the first step of splicing 144. Work of the Vilardell’s group 
documented the rules that govern 3SS selection in Saccharomyces cerevisiae, 
revealing a widespread role for the RNA secondary structure in the intronic region 
between the BP and the 3SS in this selection (Figure 5.1A). In yeast, a 3SS has to be 
located within a window of 10 to 45 nucleotides from the BP, either linearly or via folded 
RNA. All splice sites within this window, but outside a stem, will be used by the 
spliceosome machinery with a preference for YAG. A region of 9 nt downstream the 
BP will not harbour any structure and likewise AGs located here will be ignored 128.  
In A3SS-T11, the 3SS and A3SS are located in the window of 45 nt, based on the 
detected BP (Figure 4.12C). In human genes, the Py-tract plays an essential role in 
the splicing process and is mostly absent in yeast. It acts at an early stage of 
spliceosome assembly point and it is required for the first step of the catalytic process. 
The length of the Py-tract and its composition are important in 3SS recognition 145, 146. 
It was observed that Py-tract location relative to the aptamer position as well as their 
nucleotide composition highly influences the selection of the 3SS and significantly 
affects the switching properties (Figure 4.11). 
 
 
Figure 5.1 Mechanisms of 3SS recognition. (A) 3SS definition in Saccharomyces cerevisiae introns. 
Numbers indicate the distance to the branch point sequence (BP) A in nucleotides (nt). Stems are not 
considered by the spliceosome when determining this distance, and included AGs (red) are therefore 
not used. AGs preceded by a pyrimidine (green) are favoured over AAG (orange), otherwise the latter 
are used efficiently. Predicted stems in the first 9 nucleotides after the BP are not compatible with 
splicing, and AGs in this zone are not used as 3SS (adapted from 128). (B) Molecular interactions at the 
3SS within the spliceosomal E (upper panel) and A (below panel) complexes (adapted from 90). 
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For A3SS-T11, the Py-tract is located between the aptamer stem and 3SS, where the 
stem is likely required to reduce the distance between the BP and the 3SS. Also Py-
tract can be separated by the aptamer in A3SS-T1, where the aptamer presumably 
brings together Py-tract sequences to facilitate the recognition to binding proteins to 
these sequences such as the U2AF65 (Figure 5.1B). Unexpectedly, though, upon TetR 
binding to the aptamer, A3SS is activated. It contradicts other works where it was 
shown that the recognition of 3SS is blocked when ligands bind to the aptamer 58,61. 
Presumably the aptamer position at the 3’ end of the intron interferes with the SF1-
U2AF65 and U2AF65-U2AF35 interaction during spliceosomal assembly. The 
spliceosome scanning mechanism from the selected BP may be blocked by the TetR-
RNA complex resulting in a yet unexplained recognition of A3SS by the spliceosome 
machinery. Probably the accumulation of splicing factors next to the stem lead to its 
opening, as the same splicing pattern is observed for A3SS-T14 construct with a 
stabilized aptamer stem, where A3SS is recognized even without TetR, but it does not 
exhibit switching behaviour (Figure 4.12A). As in mammalian genes the mechanism of 
3SS selection is still not fully understood, the application of aptamers may provide an 
additional strategy to study mechanism of alternative splicing in these cells.  
 
5.2.1 Evaluation of the proposed model to control nuclear import 
The TetR aptamer system to control an A3SS was established in the context of egfp 
reporter gene. Following a successful demonstration of the producing of two splice 
variants on the mRNA level, this model was also confirmed on the protein level. 
Proteins smaller than 60 kDa or up to a diameter of 9 nm can passively diffuse into the 
nucleus 147. EGFP is a protein with a molecular mass of 27 kDa and diameter of 2.4 
nm 148. Therefore, the strategy was to fused EGFP to a cytosolic protein in order to 
prevent passive diffusion into the nucleus. The EGFP fused to the SERPINE1 mRNA-
binding protein 1 (SERBP1) with a molecular mass of 122 kDa shows predominant 
cytoplasm localization (Figure 4.16). This protein contains arginine and glycine rich 
motifs, which may lead to the accumulation inside nucleoli when it is transported into 
the nucleus 149, 147.  
The system could be tested with different reporter gene that does not migrate to the 
nucleus via passive diffusion. Additionally, the EGFP fusion to other cytosolic proteins 
such as GTPase activating protein (SH3 domain) binding protein 1 (G3BP1) or 
adenosine monophosphate deaminase 2 (AMPD2) could be tested. Also, it was 
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observed that the TetR concentration based on mCherry expression in the cells has 
an impact on the switching properties. In cells, with an overly low or overly high TetR 
expression, it was not detected EGFP accumulation in the nucleus. An insufficient TetR 
concentration does not lead to activation of A3SS and therefore does not produce a 
nuclear splice variant. In turn, overexpression of TetR can lead to metabolic stress and 
pleiotropic effects in the cells. 
 
Unfortunately, the attempt to produce two splice variants with mitochondrial or nuclear 
distribution with TetR system proved unsuccessful. Based on the RT-PCR results for 
A3SS-TN2-MLS, the A3SS is activated in the presence of TetR and second splice 
variant carrying MLS is produced. The microscopic images of the NLS-MLS-EGFP 
control show EGFP primarily localized in the nucleus. It is possible that the additional 
aptamer-born amino acids lead to not proper folding and masks the NLS 150 or NLS-
MLS sequence may be cleaved off upon import into mitochondria. Most of the N-termini 
of mitochondrial proteins carrying a MLS are cleaved off by the heterodimer 
mitochondrial processing peptidase in the matrix and some of them are further cleaved 
by intermediate peptidase such as Oct1 or lcp55 151, 152. Additionally, the strong COX8A 
could be exchanged by the weaker mitochondrial signal.  
 
Finally, in theory any targeting signals involved in protein relocalization can be 
controlled by our device including signals for nuclear export, mitochondrial, peroxisome 
signal, or any sequence of interest. This model could also be used for functional 
characterization of individual proteins involved in different cellular functions, 
determining mislocalization of disease-causing mechanisms. 
 
5.3 Blocking a ribosomal scanning with the TetR aptamer complex 
Ribosomal scanning through structural barriers within the 5’ or 3’ UTRs of eukaryotic  
mRNA transcripts was found to be an important regulatory step 153, 154, 155. RNA 
structures located in the 5’ UTRs are important to this regulation by affecting ribosomal 
recruitment and positioning at a favourable start codon. The main rate-limiting step of 
translation initiation is determined by the binding of the 43S pre-initiation complex 
(composed of the 40S ribosomal complex, initiation factors eIF3 eIF1, eIF1A, eIF5, and 
eIF2-GTP-met-tRNA) to mRNA via the eIF4 initiation factor complex (eIF4E, eIF4A, 
eIF4G, and eIF4B) 156, 157. The 5’ methyl G cap is recognized by initiation factor eIF4E. 
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Under favourable translation conditions, eIF4G serves as a scaffold bridging the 
ribosome to the mRNA cap by binding eIF4E, eIF4A, and eIF3. Initiation factor eIF4A 
exhibits RNA helicase activity and is thought to assist the eIF4F complex in unwinding 
mRNA secondary structure, creating a binding site for the 43S initiation complex. The 
43S complex then scans along the mRNA until it reaches a start codon.  
Previous studies have shown that the introduction of a small molecule binding aptamer 
into the 5′ UTR of an mRNA can confer regulated expression of both prokaryotic and 
eukaryotic reporter genes 19, 50. However, work on tetracycline and neomycin 
riboswitches indicated that the transfer of a yeast-optimized variant to higher 
eukaryotes is challenging, probably due to the increased helicase activity of the 
ribosome in mammalian compared to yeast cells. Translation control with the 
ciprofloxacin aptamer only exhibits up to 1.8-fold in HeLa cells 136, which indicate that 
the full potential of aptamer mediated translation control in human cells has been far 
from realised to date. 
Results in this project are consistent with a model in which translational initiation is 
blocked by the aptamer-complex in the 5′ UTR. Placing TetR aptamer within 5’ UTR of 
egfp reporter gene allows for reversible and efficient control of translation in HeLa cells.  
Interestingly, the aptamer structure in the 5’ UTR in T6 construct did not reduce the 
basal expression (and only marginally in TT4) in the absence of TetR compared to the 
EGFP control without the aptamer.  
 
Figure 5.2 Evaluation of translation regulation with the aptamer. Display of the constructs with 
different aptamer thermal stability (ΔG kcal/mol) and EGFP fluorescence in the presence of dox (ON 
state) or in its absence (OFF state) and dynamic range (x-fold). The triangle indicates T6 construct with 
the highest regulation. 
 
In regard to aptamer thermal stability, it is was observed that increasing predicted 
thermal stability of mRNA leads to a decrease in translation (T2-T11; Figure 5.2), which 
agrees with previous studies 52, 158. The steepest fall-off in translation efficiency occurs 
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when aptamer-predicted stabilities increase from -28 to -42 kcal/mol and the translation 
efficiencies remained consistent between the stabilities of -14 and -25 kcal/mol. The 
majority of constructs exhibit an EGFP fluorescent between 10-20% in the repressed 
state. Only T9 construct with the shortest aptamer stem shows approximately 55%. 
Moreover, most of the constructs exhibit regulation from 5- to 6.7-fold, and the 
maximum 8.5-fold is observed for T6 with -23 kcal/mol aptamer stability. Interestingly, 
the removal of three base pairs of the closing stem of T2 results in an increased 
dynamic range. This may suggest that the initial design of the aptamer stem with a 
length of 9 base pairs would show the highest switching properties if not the influence 
of possible additional binding of surrounding sequences. Mutations that destroy TetR 
binding were introduced in construct T6 with the best regulation properties (T6*). It 
leads to a complete loss of regulation indicating that switching is indeed mediated by 
TetR aptamer interaction. Additionally, for T6 and T6* constructs qPCR analysis were 
performed and no significant changes were observed in the present of TetR and with 
or without dox on mRNA level [data not shown]. This confirms that the control occurs 
at the translational level and is due to a specific interaction between TetR and the RNA 
aptamer. 
In this study the significance of the aptamer position on translation was observed. 
Similar effects that in mammalian cells mRNA structure is more inhibitory when is 
proximal to the 5’ mRNA cap were already shown in others studies 153 (T2 and T32, 
displayed in Figure 4.26). Reduced egfp expression in T32 exhibits lower regulation 
than T2, which can be related due to movement of both the inhibitory structure at the 
5’ cap proximity and the start codon, which is located within the aptamer sequence. 
Constructs TT1 and TT2 that contain two aptamers at the cap-distal position do not 
lead to tighter translation repression. The aptamers in TT1 and TT2 are separated by 
30 nt spacer, that does not form any secondary structures and may thus be seen solely 
as an insulation module to minimize global folding constrains between the two RNA 
architectures 159. However, it is still probable that an additional global- or self-folding 
between the same aptamer stems occurs, which could explain the lower regulation 
compared to the single aptamer. In contrast, the cap-proximal and -distal aptamers 
placement in TT2 as well as the additional third aptamer in the middle of the 5’ UTR 
has higher effect on regulation control. It is possible that different steps of translation 
initiation are being inhibited by TetR, depending on whether the aptamer is cap- 
proximal or distal. Cap-proximal insertion may inhibit binding of the 43S complex to the 
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cap structure whereas the cap-distal aptamer may interfere with formation of the 80S 
ribosome, presumably by blocking the scanning preinitiation complex  33, 160. 
In addition to thermal stability and distance effects, translation efficiency was 
dependent on the GC content of the aptamers closing stem. Constructs T1 and T6 
both have predicted thermal stability around -23 kcal/mol but differ in GC content. 
Notwithstanding, T6 with high GC content shows regulation up 8.5-fold and T1 only 
regulation up 2.5-fold. The same pattern is observed for constructs T4 and T21 with 
predicted thermal stability of -28 kcal/mol, but their regulation is up to 6.5- and 1.7-fold, 
respectively. In has been reported that the GC content affects protein-translation 
efficiency independent of hairpin thermal stability and hairpin position 158. It seems that 
local stability per base has an effect on translation efficiency, since compact, thermally 
stable hairpins composed of GC bonds are harder to melt than hairpins composed of 
weaker AU bonds. Presumably RNA structures with predicted thermal stabilities 
stronger than -50 kcal/mol may still be efficiently translated as long as the GC content 
of the stem is relatively low. Less stable RNA structures with high stem GC content 
may inhibit translation more than stable structures with low GC content. The scanning 
ribosome does not melt the entire hairpin in a concerted event, but rather tries to 
bulldoze through the obstacle in a progressive, relatively local unzippering. High GC 
content confers high stability per base pair, perhaps exceeding the force available to 
the translation machinery 158. 
In this project an efficient translation control system in mammalian cells was developed 
that meets the desirable features that often prove a major challenge in implementing 
synthetic biology in mammalian cell lines. The TetR aptamer based translation 
regulation system could be broadly applicable for reconstructing and interrogating 
native translation control mechanisms, as well as for designing novel cellular functions. 
Modularity and applicability of the system have been demonstrated by regulation of 
endogenous genes as well as with the TetR aptamer in the context of other 5’ UTRs. 
Another approach would be to combine the TetR aptamer based translation regulation 
system with other systems that control gene expression at transcriptional or post-
transcriptional level to achieve a tighter control of gene expression as was 
demonstrated by the dual control at the splicing and translation level. In summary, 
these studies allow for better understanding how translation is regulated in human cells 
and in addition could be useful in the design of artificial systems for controlling 
translation process in mammalian cells. 
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5.4 Transcriptional- versus post-transcriptional-based regulatory systems 
Synthetic biology has pioneered transformative genetic devices that enable the study 
of cellular and molecular biology in cells. Mammalian regulatory devices use diverse 
mechanisms to allow flexible, precise, and comprehensive control over gene 
expression and cellular development 10. Fine tuning of gene expression is critical for 
many synthetic biology applications and can be achieved at the transcriptional and 
post-transcriptional levels. Transcriptional control received the most attention in terms 
of synthetic devices to regulate gene expression in preference to other levels of control. 
Transcription-based regulatory systems provide access to large dynamic ranges that 
allow gene expression to be titrated to a level appropriate for the specific application. 
The dynamic ranges achievable in translational and posttranslational control systems 
are modest and higher basal expression levels are observed in the repressed state. 
Synthetic regulators that have both high dynamic range and low basal activity are still 
a challenge in the synthetic biology, especially in mammalian cells 161.  
The advantages of transcriptional regulation are that there is remarkable flexibility in 
the design space for promoter sequences and DNA binding proteins and that known 
modules can be composed into larger systems. The response of a promoter to different 
inputs can be regulated by changing its repressor binding sites, introducing point 
mutations within its sequence or screening randomized libraries. Additionally, 
transcription can be controlled with synthetic TAL effector and zinc finger proteins as 
well as with the CRISPR Cas9 system or small transcription activating RNAs 162, 163, 
164, 165, 166. However, a transcriptional regulation is limited due to the loading effects, 
limited number of orthogonal regulators, and the time that it takes to process each step 
of gene expression. Moreover, some of the used transcriptional repressors often 
modified the chromatin structure surrounding the synthetic construct, and 
consequently epigenetic effects may lead to slow reactivation of many transcriptional 
regulators. While bacterial promoters are relatively easy to manipulate, their 
mammalian counterparts require more complex transcriptional machinery that varies 
among different cell types and states, which is limiting the generality and practical utility 
of synthetic promoters. Notwithstanding, synthetic promotors may also lead to 
metabolic burden and pleiotropic effects as a consequence of unnecessary 
overexpression 167, 168, 169 170.  
Recently, there has been an increased effort to develop RNA based post-
transcriptional tools to indirectly influence translation via mRNA stability and splicing 
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or to directly control translation by affecting ribosomal scanning. Most of post-
transcriptional events such as alternative splicing or other RNA-based mechanisms 
like miRNAs, are often found in the lower dynamic range 171. The low regulation from 
2- to 4-fold also was observed in the RNA-based systems that interfere with the splicing 
mechanisms, although it was sufficient to trigger the cell death 61, 74.  Interestingly, the 
developed systems in these studies for splicing and translation control with the TetR 
aptamer shows a higher dynamic range up to 11-fold and low basal activity, what it 
represent a considerable improvement of the existing RNA regulators on the post-
transcriptional level in human cells.  
The translational regulation become an attractive approach used in mammalian gene 
regulation with various advantages over the transcriptional control. It allows for 
independent regulation from those sequence elements that are responsible for 
regulation at the DNA level. Once mRNA is transcribed, the genomic context 
surrounding the synthetic construct becomes irrelevant. Next, the dynamics of 
translational regulation are faster due to the skipping of the transcription step in gene 
expression and may be used for regulating processes on the medium timescale, such 
as feedback regulation to balance protein levels in therapeutic or metabolic circuits. 
Moreover, translational regulation can be directly interfaced with various cytoplasmic 
components of the cell. RNA aptamers may directly be utilized and incorporated into 
proteins or small molecule responsive translational regulators 162, 169.  
A decrease of the metabolic burden can be achieved if RNA regulators are used 
instead of protein regulators of either transcription or translation. Production of RNA is 
cheaper in terms of nutrient requirements and does not divert ribosomal resources 
away from the translation of other cellular proteins. However, the RNA binding 
proteins-based devices contribute to the synthetic design by enhancing the regulatory 
effects compare to the small molecule responsive RNA switches 72.  
As synthetic systems become more sophisticated, they will adapt a combination of 
transcriptional and various post-transcriptional regulators. There are an increasing 
number of new tools for translational regulation with a potency for future applications 
in mammalian synthetic biology 162, 172.  
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6 Material and Methods 
 
Plasmid construction 
Plasmids were constructed by standard cloning techniques using overlap extension  or 
fusion PCR with Q5 Polymerase (NEB) and restriction and ligation reactions with HF 
restriction enzymes (NEB) and T4-DNA ligase (NEB), respectively. Custom 
oligonucleotides were synthesised by Sigma Aldrich. First, the gfp gene was cloned 
into pcDNA5/FRT vector, under CMV promotor, using the unique restriction sites for 
BamHI and NotI, resulting in EGFP* construct. Next, first the exon from CI4T5 
construct, the complete intron with TetR aptamer and six nucleotides from the second 
exon were cloned into EGFP* by unique restriction sites for SpeI and MluI, resulting in 
the  construct SP. All modifications of SP were done by overlap extension PCR and 
amplicon insertion by unique restriction sites for SpeI and MluI. Further, the mCherry 
or MAX genes were cloned into SP_cr by unique restriction sites for BamHI and NotI, 
resulting in the TSD_mCherry and TSD_MAX-GFP. Next, the MINX intron with flanking 
exon sequences 127 was placed in front of egfp reporter gene,  generating MINX-EGFP. 
This construct was used for insertion the TetR aptamer resulting in A3SS-T1 and 
A3SS-T2. All modifications of A3SS-T2 were done by overlap extension PCR and 
amplicon insertion by unique restriction sites for SpeI, MluI, AgeI or KpnI. Furthermore, 
EGFP* construct was used to insert the TetR within 5’ UTR resulting in T1-T3 
constructs and then all modifications of T2 were done by overlap extension PCR and 
amplicon insertion by unique restriction sites for BamHI and NotI. 
TetR protein was express under the CMV promoter and was modified at the N-terminus 
with a nuclear localization signal from c-MYC. The construct expressing TetR-mCherry 
was cloned by insertion of the mCherry gene into TetR expressing plasmid with unique 
restriction sites for KpnI and AgeI.    
 
Table 6.1 Used the nuclear (NLS) and mitochondrial (MLS) localisation signals and ‘self-cleavage’ 
sequence (P2A). 
 
 
Sequence name Sequence (5' - 3') 
NLS: c-MYC CCGGCCGCGAAACGCGTGAAACTGGAT
MLS: COX8A ATGTCCGTCCTGACGCCGCTGCTGCTGCGGGGCTTGACAGGCTCGGCCCGGCGGCTCCCAGTGCCGCGCGCCAA GATCCATTCGTTG
MLS: GLS ATGATGCGGCTGCGAGGCTCGGGGATGCTGCGGGACCTGCTCCTGCGG
P2A GGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCCTGGACCT
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Table 6.2 PCR mixture  
 
 
Table 6.3 Overlap extension PCR program 
 
 
Table 6.4 Fusion PCR program 
 
 
Table 6.5 PCR colony mixture  
 
 
Table 6.6 PCR colony program  
 
 
 
 
Reagent volume [μL]
Q5® reaction buffer (x5) 20
primer F (10 μM) 3
primer R (10 μM) 3
dNTPs (10 mM) 2
template (100 ng/μL) 1
Q5® DNA Polymerase (2 U/μL) 1
H20 ad 100
Step Temperature [°C] Time
Initial denaturation 98 30 s
Denaturation 98 15 s
Annealing 56-62 20 s
Extension 72 20 s/kb
Final extension 72 5 min
x35
Step Temperature [°C] Time
Denaturation 98 2 min
Annealing 58 2 min
Extension 72 30 min
Reagent volume [μL]
Taq DNA reaction buffer (x10) 2.50
primer F (10 μM) 0.75
primer R (10 μM) 0.75
dNTPs (10 mM) 0.75
bacterial cell 1.00
Taq DNA Polymerase (5 U/μL) 0.25
H20 ad 25.00
Step Temperature [°C] Time
Initial denaturation 94 2 min
Denaturation 94 30 s
Annealing 54 30 s
Extension 72 45 s
Final extension 72 5 min
x30
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Table 6.7 Digestion mixture 
 
 
Table 6.8 Ligation mixture 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagent volume [μL]
Cut Smart buffer (x10) 5
restriction enzyme I (0.4-0.8 U/μl) 1
restriction enzyme II (0.4-0.8 U/μl) 1
DNA (2-5 μg) 10
H20 ad 50
Incubation: 37°C; 1-2 h
Reagent volume [μL]
T4 DNA ligase buffer (x10) 2
backbone (25 ng) 1
insert (x ng) 1
ATP (10 mM) 2
T4 DNA ligase (400 U/μl) 1
H20 ad 20
Incubation: RT; 1-2 h
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Figure 6.1 Plasmid map of pcDNA5/FRT. All constructs were cloned into pcDNA5/FRT 
under CMV-promoter (Invitrogen). 
 
Figure 6.2 Plasmid map of CMV_TetR. Plasmid expressing under the CMV promoter the TetR protein. 
Based on this plasmid was cloned the TetR tagged with mCherry and additional plasmid expressing 
TetR-mCherry with NLS. 
 
 
Figure 6.3 Plasmid map of pOG44. Plasmid expressing the Flp-recombinase and was used for stable 
integration (Invitrogen). 
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Table 6.9 Primers used for cloning. 
 
Primer name Sequence (5' - 3') 
EGFP*_F CACAGGATCCACTAGTATGACAAGTTCAACGCGTGTGAGCAAGGGCGAGGAGCTGTTCACCGGG
EGFP*_R CTCGAGCGGCCGCTTACTTGTACAGCTCGTCCATGCCGAGAG
SP_F GAAGATGCCAAAAACATTAAGAAGGG
SP_R TCACACGCGTCGCTGGCTGTGGAGAGAAAGGC
SP_cr_F ATCCACTAGTATGGAAGATGCCAAAAACATTAAGAAGGGCGTAAGTCTATCAAGCAGCATGTTATGG GTCATCACAGACCAGAGAAAAGCTTG
SP_cr_1_F ATCCACTAGTATGGAAGATGGCAAAAACATTAAGAAGGCCGTAAGTCTATCGCAGCATGTTATGGGT CATCACAGACCAGAGAAAAGCGATAGATCAAGGTTACAAG
SP_cr_2_F ATCCACTAGTATGGAAGATGGCAAAAACATTAAGAAGGCCGTAAGTCTAGCAGCATGTTATGGGTCA TCACAGACCAGAGAAAAGCTAGATCAAGGTTACAAG
SP_cr_3_F ATCCACTAGTATGGAAGATGGCAAAAACATTAAGAAGGCCGTAAGTCGATCCCGCAGCATGTTATG GGTCATCACAGACCAGAGAAAAGCGGGATCGATCAAGGTTACAAG
SP_cr_4_F ATCCACTAGTATGGAAGATGCCAAAAACATTAACAAGGGCGTAAGTG
SP_cr_5_F ATCCACTAGTATGGAAGATGGCAAAAACATTAAGAAGGCCGTAAGTG
SP_cr_6_F ATCCACTAGTATGGAAGATGGCAAAAACATTAACAAGGCCGTAAGTG
SP_cr_7_F ATCCACTAGTATGGAAGATGCCAAAAACAGGAAGAACGGCGTAAGTCTATCAAGCAGCATG
SP_cr_8_F ATCCACTAGTGAAGATCATCAAAAACATTAAGAAGGATGGTAAGTGTATCAAG
SP_cr_9_F ATCCACTAGTGAAGATGGCAAAAACATTAACCATGGCCGTAAGTC
SP_cr_10_F ATCCACTAGTGAAGATGCCAAAAACGCCACCATGGGCGTAAGTC
SP_cr_11_F ATCCACTAGTATGATTAAGAAGGGCGTAAGTCTATCAAGCAG
SP_cr_12_F ATCCACTAGTATGGAAGACGCCAAAAACATTAAGAAG
SP*_F CAGCGACGCGTGGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAG AACCCTGGACCTGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGC
TSD_mCherry_F CCAGCGACGCGTGGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGG AGAACCCTGGACCTGTGAGCAAGGGCGAGGAGGATAACATG
TSD_mCherry_R TGTGGCGGCCGCCTACTTGTACAGCTCGTCCATGCCGCCGGTGGAGTG
TSD_mCherry-1_F CCAGCGACGCGTGGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGG AGAACCCTGGACCTGTGAGCAAGGGCGAGGAGGATAACATAGCCATCATCAAGGAG
MAX-GFP_F CCAGCGACGCGTGGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGG AGAACCCTGGACCTAGCGATAACGATGACATCGAGGTGG
MAX-GFP_R GCCCCAAAGCAGGAAGAAGCTCCGGATGGAGGCCAGCTCAGGAGGCGGTGGATCTGTGAGCAAG GGCGAGGAGCTGTTCACCGG
TetR-mCherry_F GCGGCGACTCAGGAGGCGGTGGATCTGGTACCGTGAGCAAGGGCGAGGAGGATAAC
TetR-mCherry_R CATCACCGGTTTACTTGTACAGCTCGTCCATGCCG
TetR-KpnI_F CCCCGAATTCACCATGCCGG
TetR-KpnI_R CATGTTATCCTCCTCGCCCTTGCTCACGGTACCAGATCCACCGCCTCCTGAGTCG
EGFP_NotI_R GTGTGGCGGCCGCTTACTTGTACAGCTCGTCCATGCCGAGAGTGATCC
T1_F CACACAGGATCCGCGTGTTACAGCATGTTACGGGTCATCACAGACCAGAGAAAAGTAACACGCGGAAGCGGAGCTACTAACTTCAGCCTGCTG
T2_F CACACAGGATCCGCGCGCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGG  CGCGCGGAAGCGGAGCTACTAACTTCAGCCTGCTG
T3_F CACACAGGATCCGCGTGTTACAGCATGTTATGGGTCATCACAGACCAGAGAAAAGTAACA  CGCGGAAGCGGAGCTACTAACTTCAGCCTGCTG
T4_F CACACAGGATCCCGCGCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGCG  CGGGGAAGCGGAGCTACTAACTTCAGCCTG
T5_F CACACAGGATCCGCGCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGCGC   GGGGAAGCGGAGCTACTAACTTCAG
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T6_F CACACAGGATCCCGCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGCGGG  AAGCGGAGCTACTAACTTCAGCCTG 
T7_F CACACAGGATCCGCCGCAGCATGTTACGGGTCATC
T8_F CACACAGGATCCCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGGGGGAA   GCGGAGCTACTAAC
T9_F CACACAGGATCCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGGAAGCGG   AGCTACTAACTTCAG
T10_F CACACAGGATCCGCGCGCGCGCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAG   CGGCGCGCGCGCGGGGAAGCGGAGCTACTAACTTCAGC
T11_F CACACAGGATCCGCGCGCGCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGG  CGCGCGCGGGAAGCGGAGCTACTAACTTCAGC
T12_F CACACAGGATCCGCGCGAAGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCTTCGCGCG GAAGCGGAGCTACTAACTTC
T13_F CACACAGGATCCTCCCAGATCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGATCTGGGAGG AAGCGGAGCTACTAACTTCAGCCTGCTG
T14_F CACACAGGATCCTCCCGGATCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGATCCGGGAGG AAGCGGAGCTACTAACTTCAGCCTGCTG
T15_F CACACAGGATCCAGGGGATCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGATCCCCTGGGA AGCGGAGCTACTAACTTCAGCCTGCTG
T16_F CACACAGGATCCTCGCGCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGCGCGAG GAAGCGGAGCTACTAACTTCAGCCTGCTG
T17_F CACACAGGATCCTCGCGCTGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCAGCGCGAGG AAGCGGAGCTACTAACTTCAGCCTGCTG
T18_F CACACAGGATCCTCGTGCTGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCAGCACGAGG AAGCGGAGCTACTAACTTCAGCCTGCTG
T19_F CACACAGGATCCAGCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGCTGGAAGCG GAGCTACTAAC
T20_F CACACAGGATCCACGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGTGGGGAAGCGGA GCTACTAAC
T21_F CACACAGGATCCTTTGCGTGTTACAGCATGTTACGGGTCATCACAGACCAGAGAAAAGTAACACG CAAAGGAAGCGGAGCTACTAACTTCAGCCTG
T22_F CACACAGGATCCGCGCGCTGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGC
T23_F CACACAGGATCCGCGCGCTGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGCGTGCG GAAGCGGAGCTACTAAC
T24_F CACACAGGATCCTGCCGCAGCATGTTACGGGTCATC
T25_F CACACAGGATCCGCGCGACGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCG
T26_F CACACAGGATCCGCGCGCCAGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGC
T27_F CACACAGGATCCGCGCGCCAGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGCGACG CGGGGAAGCGGAGCTACTAACTTC
T28_F CACACAGGATCCGCGCGCCGCAGCATGTTACGGGCCGAAAGGCCAGAGAAAAGCGGCGCGCGG GGAAGCGGAGCTACTAACTTC
T29_F CACACAGGATCCGCGCCGCAGCATGTTACGGGCCGAAAGGCCAGAGAAAAGCGGCGCGGGAAG CGGAGCTACTAACTTCAGCCTG
T30_F CACACAGGATCCGCGCGCCGCAGCATGTTACGGGCCTTCGGGCCAGAGAAAAGCGGCGCGCGG GGAAGCGGAGCTACTAACTTC
T31_F CACACAGGATCCGCGCCGCAGCATGTTACGGGCCTTCGGGCCAGAGAAAAGCGGCGCGGGAAGC GGAGCTACTAACTTC
T32_F CTAGAGTACTCGTACGCACACAGGATCCGGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGG CTGGAGACG
T32_R CGTCTCCAGCCTGCTTCAGCAGGCTGAAGTTAGTAGCTCCGCTTCCGGATCCTGTGTGCGTACGAG TACTCTAG
T33_F CACACAAAGCTTGCGCGCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGCGCGCG ATTCTTCTGACACAACAGTCTCGAACTTAAGC
T33_R GTGAACAGCTCCTCGCCCTTGCTCACCATGGATCCTGTGTGCGTACGAGTACTCTAGCCTTAAG
T33_2F CTTAAGGCTAGAGTACTCGTACGCACACAGGATCCATGGTGAGCAAGGGCGAGGAGCTGTTCAC
T2*_F CACACAGGATCCGCGCGCCGCAGTATGTTACAGGTCATCACAGACCAGAGAAAAGC
T6*_F CACACAGGATCCCGCCGCAGTATGTTACAGGTCATCACAGACCAG
TT1_F AGTACTCGTACGGACACAGCGCGCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGC GCGCGGAGAGGCG
TT1_R GCGCGCGGATCCGCCTCCGCGCTTCTTAATGTTTTTCGCCTCTCCGCGCGCCGCTTTTCTCTGGTC 
TT2_F GGAGGCGGATCCGCGCGCGCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGCGCG CGGGAAGCGGAGCTACTAACTTC
TT3_R GTGTGCGTACGAGTACTCTCGCCTTCAGAGCTGTAATTGAACTGGGAGTGGACACCTGCCCAGTGC CTCGACCAACTTCTG
TT4_F TGTGTGCGTACGAGTACTCTCGCCTTCAGAGCTGTAATTAAGCGCGCCGCTTTTCTCTGGTCTGTGA TGACCCGTAACATGCTGCGGCGCGCAACTTCTGCAGCTTAAGTTCGAGAC
del_NLS_TetR_F GGCCCCGAATTCACCATGTCTAGACTGGACAAGAGCAAAGTCATAAAC
  Material and Methods  
[73] 
 
 
T2-SP*_F CACACAGGATCCGCGCGCCGCAGCATGTTACGGGTCATCACAGACCAGAGAAAAGCGGCG CGCGGAAGCGGAGCTACTAACTTCAGCCTGCTG
MINX_F
ATCCGGAAACCCGTCGGCCTCCGAACGGTAAGAGCCTAGCATGTAGAACTGGTTACCTGCAGCCCAA
GCTTGCTGCACGTCTAGGGCGCAGTAGTCCAGGGTTTCCTTG
MINX_R
ATCACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAAAAAGGGACAGGATAAGTATGTCGG
TACCTCATCAAGGAAACCCTGGACTACTGCGCCCTAGAC
MINX-EGFP_F ATCCACTAGTATGCGGAAACCCGTCGGCCTCCGAAC
MINX-EGFP_R
TCACACGCGTACCGGTGAAGAGTTTGTCCTCAACC
A3SS-T1_F
GATGAGGTACCGACATACTTATCCTGTCCCTTTTGCATGTTACAGCATGTTATGGGTCATCACAGACCAG
AGAAAAGTAACATGC
A3SS-T1_R
ACGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAGCATGTTACTTTTCTCTGGTCTGT
GATGACCC
A3SS-T2_F
GATGAGGTACCGACATACTTATCCTGTCCCTTTTGCATGTTACAGCATGTTATGCCTCATCACCGAGGAG
AGAAAAGTAACATGC
A3SS-T2_R
ACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAGCATGTTACTTTTCTCTCCTCGGTGATGA
GGC
A3SS-T3_F
GATGAGGTACCGACATACTTATCCTGTCCCTTTTGCGCCAGCATGTTATGGGTCATCACAGACCAGAGA
AAAGGCGC
A3SS-T3_R
ACGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAGCGCCTTTTCTCTGGTCTGTGAT
GACCC
A3SS-T4_F ATCCACTAGTCGGAAACCCGTCGGCCTCCGAACGATGGTAAGAGCCTAG
A3SS-T4_R
TCACACGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAGCATGCCACTTTTCTCTGG
TCTGTGATGACCCATAACATGCTGTGGCATGCAAAAGGGACAGG
A3SS-T5_R
TCACACGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAGCATGTTCCTTTTCTCTGG
TCTGTGATGACCCATAACATGCTGGAACATGCAAAAGGGACAG
A3SS-T6_R
TCACACGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAGGCATGTTACTTTTCTCTG
GTCTGTGATGACCCATAACATGCTGTAACATGCCAAAAGGGACAGGAT
A3SS-T7_F
GATGAGGTACCGACATACTTATCCTGTCCCTTTTGCATTGTGTTACAGCATGTTATGGGTCATCACAGAC
CAGAGAAAAGTAACACGATGC
A3SS-T7_R
GCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAGCATCGTGTTACTTTTCTCTGGTCT
GTGATGACCC
A3SS-T8_F
GATGAGGTACCGACATACTTATCCTGTCCCTTTTGCATGTTCCAGCATGTTATGGGTCATCACAGACCAG
AGAAAAGGAACATGC
A3SS-T8_R
CGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAAAAAGCATGTTCCTTTTCTCTGGT
CTGTGATGACCC
A3SS-T9_F
GATGAGGTACCGACATACTTATCCTGTCACGATCGCATGTTCCAGCATGTTATGGGTCATCACAGACCA
GAGAAAAGGAACATGC
A3SS-T9_R
ACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAGCATGTTCCTTTTCTCTGGTCTGTGATGAC
CC
A3SS-T10_R
TCACACGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTTTTCCGGAAAAGGCATGTTACTTTT
CTCTGGTCTGTGATGACC
A3SS-T11_R
CTCACACGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAAAGGCATGTTACTTTTCT
CTGGTCTGTGATGACCCATAACATGCTGTAACATGCCAAAGGACAGGATAA
A3SS-T11*_R
CTCACACGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAAAGGCATGTTACTTTTCT
CTGGTCTGTGATGACCTTTAACATACTGTAACATGCCAAAGGACAGG
A3SS-T12_R
CTCACACGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAAAAAGGCATGTTACTTTT
CTCTGGTCTGTGATGACCCATAACATGCTGTAACATGCCAAAAGGGACAGG
A3SS-T13_F
GATGAGGTACCGACATACTTATCCTGTCTTTTGCACGTTACAGCATGTTATGGGTCATCACAGACCAGAG
AAAAGTAACGTGC
A3SS-T13_R
GCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAAAAAAAAAGCACGTTACTTTTCTCT
GGTCTGTGATGACCC
A3SS-T14_R
ACGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAAAGGCACGCCACTTTTCTCTGG
TCTGTGATGACCCATAACATGCTGTGGCGTGCCAAAGGACAGGATAAG
A3SS-TN1_F
CTTGCTGCACGTCTAGGGCGCAGTAGTCCAGGGTTTCCTTGATGAGGTACCGACATACTTATCCTGTCC
TTTGGCATGTTACAGCATGTTATGGATCCGGCCGCGAAACG
A3SS-TN1_R
TCACACGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGGGAAAAAAGGCATGTTACTTTTCTCT
GATCCAGTTTCACGCGTTTCGCGGCCGGATCCATAACATGCTGTAACA
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RT-PCR and lariat PCR analysis  
A total of 120,000 HeLa cells per well were seeded into a 12-well plate. The cells were 
transfected with 100 ng reporter DNA and 300 ng TetR plasmid using 2 µl of 
Lipofectamine® 2000 (Life Technologies) per well according to manufacturer 
instructions. Then, 2 h after transfection, the medium was changed to DMEM with or 
without 50 µM dox, and the cells were incubated at 37°C and 5% CO2 for 24 h. RNA 
was isolated using TRIzol® (Life Technologies) according to the manufacturer’s 
protocol. Contaminating DNA was removed with the TURBO DNA-free kit (Life 
Technologies), and the RNA was quality checked on a 1% (w/v) agarose gel. Next, 1 
µg RNA was reverse-transcribed by MuLV (Applied Biosystems) using random 
hexamers (Fermentas) with the supplied buffers (10 min at 20°C, 15 min at 42°C, 5 
min at 99°C). Then, 50 ng cDNA was PCR amplified using Taq polymerase (New 
England Biolabs, initial denaturation 2 min at 96°C, 30 sec at 96°C, 30 sec at 54°C, 30 
sec at 72°C, 35 cycles) and analysed on a 3% (w/v) agarose gel. The amplified 
products were cloned (CloneJET PCR Cloning Kit, Thermo Scientific) and sequenced 
for verification. Each RT-PCR was repeated in three independent experiments. The 
same way cDNA used for lariat PCR was prepared but with the 20 cycles. Next 
products were diluted 1:20, re-amplified with nested primers, with 30 cycles and 
A3SS-TN2_F
GATGAGGTACCGACATACTTATCCTGTCCTTTGGCGGTTACAGCATGTTATGGATCCGGCCGCGAAACG
CGTGAAACTGGATC
A3SS-TN2_R
CGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGTGGAAAAAAGGCAGTTACTTTTCTCTGATCC
AGTTTCACGCGTTTCGCGGCCGGATCCAT
A3SS-TN3_F
CTTGCTGCACGTCTAGGGCGCAGTAGTCCAGGGTTTCCTTGATGAGGTACCGACATACTTATCCTGTCC
TTTGGCATGTTACAGCATGTTATGGATCCGGCCGCGAAACG
A3SS-TN3_R
TCACACGCGTACCGGTGAAGAGTTTGTCCTCAACCGCGAGCTGGGAAAAAAGGCATGTTACTTTTCTCT
GATCCAGTTTCACGCGTTTCGCGGCCGGATCCATAACATGCTGTAACA
A3SS-TN2-CP_F GATCTGGTACCCCTGGGCACTTACAGGAAGGCTTCGGCTGCGTGGTCACC
A3SS-TN2-CP_R GTGTGGCGGCCGCTTAAGCCAGAGCTGGGAATGCCTCTGGGTCATCCACATC
A3SS-TN2-CP_2F
GATGTGGATGACCCAGAGGCATTCCCAGCTCTGGCTTCAGGAGGCGGTGGATCTGTGAGCAAGGGCGA
GGAGCTGTTCACCGG
A3SS-TN2-CP_2R
CCGGTGAACAGCTCCTCGCCCTTGCTCACAGATCCACCGCCTCCTGAAGCCAGAGCTGGGAATGCCT
CTGGGTCATCCACATC
MLS-EGFP_F
GGATCCACTAGTATGTCCGTCCTGACGCCGCTGCTGCTGCGGGGCTTGACAGGCTCGGCCCGGCGGC
TCCCAGTGCCGCGCGCCAAGATCCATTCGTTGACGCGTGTGAG
NLS-MLS-EGFP_F
CACACAGGATCCACTAGTATGCCGGCCGCGAAACGCGTGAAACTGGATCTCGCGGTTGAGGACAAAC
TCTTCTCCGTCCTGACGCCGCTGCTGCTGCGGGGCTTGACAGGCTC
A3SS-TN2-MLS_F
GAGAAAAGTAACTGCCTTTTTTCCACAGCTCGCGGTTGAGGACAAACTCTTCACCGGTTCCGTCCTGAC
GCCGCTGCTGCTGCGGGGCTTGACAGGCTCGGC
A3SS-TN2-MLS_R
GCCGAGCCTGTCAAGCCCCGCAGCAGCAGCGGCGTCAGGACGGAACCGGTGAAGAGTTTGTCCTCAA
CCGCGAGCTGTGGAAAAAAGGCAGTTACTTTTCTC
MLS-GLS-EGFP_F
CTCTACAACTGTAGTATATAGAATGGAGAGTCTGGGGGAGAGGAGCGGCGACTCAGGAGGCGGTGGAT
CTACCGGTGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTG
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analyzed on a 3% (w/v) agarose gel. Bands of interest using CloneJET were cloned 
and sequenced for verification. Primers are listed below. 
 
Table 6.10 Used primers for RT-PCR and lariat PCR analysis.  
 
 
qPCR analysis  
For qPCR analysis the Fast SYBR Green Master Mix (Applied Biosystems) was used 
and the samples were analysed on a StepOnePlus Real-Time PCR machine (Applied 
Biosystems) according to the supplier’s protocol. Analysis was performed with samples 
from three independent experiments in technical replicates. Results according to the 
ΔΔCt method were calculated 173. Primers are listed below. 
 
Table 6.11 Used primers for qPCR analysis.  
 
 
 
 
Name Sequence (5' - 3') 
5SS_F GTACGCACACAGGATCCACTAGTATG
5SS_R GTGAACAGCTCCTCGCCCTTG
A3SS_F AACCCGTCGGCCTCCGAAC
A3SS_R CGCCGGACACGCTGAACTTG
lariat_1F GTCTAGGGCGCAGTAGTCCAG
lariat_1R GCAGCAAGCTTGGGCTGCAG
lariat_2F CTAGGGCGCAGTAGTCCAGG
lariat_2F GCTGCAGGTAACCAGTTCTAC
Name Sequence (5' - 3') 
spliced_1F CATTAAGAAGGGCCCAGCGAC
unspliced_1F CTTGCGTTTCTGATAGGCACC
GFP_1R AGGGTTCTCCTCCACGTCTC
actin_F CGGGACCTGACTGACTACCTC
actin_R CTTCTCCTTAATGTCACGCACG
TetR_F CGCTCAAAAGCTGGGAGTTG
TetR_R GCCTGTCCAGCATCTCGATT
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Table 6.12 qPCR mixture  
 
 
Table 6.13 qPCR program  
 
 
Agarose gel electrophoresis  
The analysis of size and quality of DNA and RNA as well as the DNA fragment 
purification was performed through applying agarose gel electrophoresis. Dependent 
on fragment size, 1% - 3% (w/v) agarose gels were used. For their fabrication, the 
respective amount of agarose was dissolved in 1x TAE and dissolved by heating in the 
microwave. The samples were mixed with 6x DNA or 2x RNA loading dye, the gel was 
run in 1x TAE and an electric field strength of 6 V/cm. Gels were stained in 0.5 μg/ml 
ethidium bromide for 15 min and DNA or RNA was visualized under UV light.  
 
Table 6.14 Composition of 50xTAE and 6x DNA loading dye. 
 
 
 
 
Reagent volume [μL]
SYBR Green Master Mix (x2) 10
Primer Mix (each 10 μM) 1
cDNA 3
H20 ad 25
Temperature [°C] Time
95 20 s 
95 3 s
60 30 s
95 15 s
60 60 s
95 15 s
x40
melting curve program
Buffer/ solution Ingredients Concentration 
Tris 2 M 
Acetic acid 1 M 
EDTA 50 mM 
pH 8.3 
Tris-HCl pH 7.6 40 mM 
EDTA 1 mM 
Acetic acid 20 mM 
Glycerol 50% (v/v) 
Bromophenol blue spatula point 
Xylene cyanole spatula point 
50x TAE 
6x DNA loading dye 
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DNA precipitation with butanol  
To concentrate DNA, 10 volumes of 1-butanol were added to the DNA solution and the 
mix was vortexed for 20 s. Then, it was centrifuged for 15 min at 13.000 rpm, washed 
with 75% (v/v) ethanol and centrifuged for 10 min at 13.000 rpm, again. After removing 
the supernatant, the pellet was dried for 5 min at RT and dissolved in 8 μl water.  
 
DNA purification  
DNA purification was conducted by using column purification or gel extraction kits. To 
purify DNA from proteins, salt, RNA and small DNA fragments, the QIAquick PCR 
Purification kit (QIAGEN) was used. To isolate DNA fragments of defined size, the DNA 
sample was run on a gel and the band of interest was excised from the gel. Gel 
extraction was performed employing the QIAquick Gel Extraction kit (QIAGEN) 
according to the manufacturer`s protocol. The pellet was dissolved in water.  
 
Plasmid preparation  
For the propagation of a plasmid in bacteria, the cells containing the desired plasmid 
were inoculated in 4 ml of LB-medium supplemented with the respective antibiotic and 
grown at 37°C shaking at 150 rpm overnight. For plasmid isolation the QIAprep®Spin 
Miniprep kit (QIAGEN) was used according to the manufacturer`s protocol. The pellet 
was dissolved in water.  
 
Table 6.15 Composition of ampicillin stock and LB and SOC medium. 
 
 
 
Buffer/ solution Ingredients Concentration 
Ampicillin (stock solution) 
Ampicillin                  
in 70% (v/v) EtOH 100 mg/ml 
Tryptone 1% (w/v) 
Yeast extract 0.5% (w/v) 
NaCl 1% (w/v) 
Ampicillin 100 µg/ml 
LB-amp plates Agar 2% (w/v) 
Yeast Extract 0.5%
Tryptone 0.2%
NaCl 10 mM
KCl 2.5 mM
MgCl2-7·H20 10 mM
MgSO4-6·H20 10 mM
LB medium 
SOC medium
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Determination of the concentration of nucleic acids 
The concentration of DNA and RNA sample was determined at 260 nm wave length 
using the NanoDrop® ND-1000 Spectrophotometer. As reference the respective 
solvent was employed. 
Preparation of electrocompetent cells 
One day before starting the preparation, two overnight cultures of 4 ml LB-medium 
containing tubes were inoculated with E.coli Top10 cells (Invitrogen) and grown at 
37°C at 150 rpm overnight. Next day, the cultures were transferred to 600 ml of LB-
medium in a 2 L baffle flask to yield a start OD600 of 0.1. The cell suspension was 
incubated at 37°C at 200 rpm. After reaching an OD600 between 0.6 - 0.8 cells were 
chilled on ice for 0.5 h, harvested by centrifugation for 20 min at 7.000 rpm and washed 
three times with 10% (v/v) of glycerol. Cells were resuspended in 4 ml of 10% (v/v) of 
glycerol and split into aliquots of 100 μl in 1 ml reaction tubes.  
Electroporation of E.coli 
Electroporation was used to transform E.coli cells. 0.5 μl of DNA were gently mixed 
with the bacteria and the mixture transferred into the slit of the micro pulser 
electroporation cuvette, 0.1 cm gap (Bio-Rad). The bacteria were electro-shocked with 
1.800 V for 5 ms. Immediately after applying the electric field to the cells, cells were 
extracted from the cuvette and mixed with 450 μl SOC-medium. After a 45 min recovery 
phase at 37°C and 1.000 rpm in the shaker, 200 μl of cells were plated onto agar plates 
containing ampicillin. Plates were incubated at 37°C overnight. 
Cell culture 
HEK293 and HeLa cells (DSMZ, No. ACC-305 and ACC-57, respectively) and HF1-3 
cells “Flp-In Host Cell Line” 174 were maintained at 37°C in a 5% CO2 humidified 
incubator and cultured in Dulbecco’s Modified Eagle Medium (DMEM, Sigma Aldrich) 
supplemented with 10% fetal bovine serum (FBS Superior, Biochrom), 100 U/ml 
penicillin (PAA, the Cell Culture Company), 100 µg/ml streptomycin (PAA, the Cell 
Culture Company) and 1 mM sodium pyruvate (PAA The Cell Culture Company). For 
HF1-3 cells, 150 μg/mL zeocin (Invitrogen) was additionally supplemented to the 
medium, whereas the medium of the HF1-3 cells harbouring the integrated constructs 
P2A_GFP, TSD_GFP, A3SS-TN2-CP and A3SS-TN2-MLS contained 200 μg/mL 
hygromycin (Invitrogen). 
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Genomic Integration 
HF1-3 cells were transfected with the plasmids pcDNA5/FRT_GFP and pOG44 
(recombinase expression plasmid, Invitrogen) at a molar ratio of 1:9 using 
Lipofectamine® 2000 (Life Technologies) according to manufacturer instructions. The 
medium was changed 24 h after transfection to DMEM. The cells were selected for 
stable integration by adding 200 µg/ml hygromycin. After two weeks of selection with 
hygromycin, cells were sorted by the S3e™ Cell Sorter (Bio-Rad) for EGFP positive 
cells and analysed for stable integration by genomic PCR and sequencing.  
 
Western blotting 
For western blot analyses, cells were transfected with the respective plasmids and 
grown over night with or without dox. Cells were lysed in T-PERTM tissue protein 
extraction reagent (Life Technology) with EDTA-free protease inhibitor (Roche) for 30 
min at 4°C. Protein concentration was measured by the Bradford method (Bio-Rad) 
according to the instructions provided by the manufacturer. 10 µg protein lysate was 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 12 %, then 
transferred to a HyBond ECL nitrocellulose membrane (Amersham) and blocked with 
Odyssey blocking buffer (LI-COR® Bioscience) for 1h at RT. The membranes were 
next incubated 1.5 h with primary antibodies that recognize GFP (Sigma-Aldrich) and 
actin (Santa Cruz Biotechnology) in 1:1000 and 1:7000 dilution, respectively. 
Membranes were washed with PBS (Invitrogen) pH 7.4/Tween20 0.1% (v/v) (Carl 
Roth) and incubated for 45 min at RT with infrared dye conjugated secondary 
antibodies IRDye® 800CW Donkey anti-Mouse IgG (Santa Cruz Biotechnology) and 
IRDye® 800CW Donkey anti-Goat IgG (Santa Cruz Biotechnology) for GFP and actin, 
respectively. Then membranes were washed with PBS-Tween buffer. Visualisation 
was carried out with Odyssey  Infrared Imaging System (Image Studio Lite; LI-COR® 
Bioscience. Three independent experiments were performed. 
 
Flow Cytometry 
A total of 120,000 HEK293 or 60,000 HeLa cells per well were seeded into a 24-well 
plate. The cells were transfected with 50 ng reporter DNA and 150 ng TetR plasmid 
using 1 µl Lipofectamine® 2000 (Life Technologies) per well according to manufacturer 
instructions. The medium was changed 2 h after transfection to DMEM (without phenol 
red) with or without 50 µM doxycycline (Sigma-Aldrich). The GFP and mCherry 
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expression was measured after 24 h using flow cytometry (CytoFlex S, Beckman 
Coulter). Mean values and standard deviations were calculated from triplicates and 
normalised to the TetR-mCherry. Each experiment was repeated three times. GFP and 
mCherry were excited using a 488 nm laser and a 550/30 filter and 561 nm laser and 
a 610/20 filter, respectively. Cells were analysed using FlowJo (TreeStar Inc., Ashland, 
OR), and populations were selected by gating out the GFP background signal of 
untransfected cells. In the case of stable integrated cells, a total of 60,000 HF1-3 cells 
expressing P2A_GFP control or TSD_GFP construct per well were seeded into a 12-
well plate. The cells were transfected with 300 ng TetR plasmid using 2 µl 
Lipofectamine® 2000 (Life Technologies) per well according to manufacturer 
instructions. The medium was changed 4 h after transfection to DMEM (without phenol 
red) with or without 50 µM doxycycline. The GFP and mCherry expressions were 
measured after 72 h using flow cytometry. Populations were selected by gating out the 
GFP background signal of untransfected cells with TetR-mCherry. 
 
Microscopic images 
Hela or HF1-3 cells expressing EGFP or A3SS-T2-CP grown on glass coverslips for 
24 h and next were transfected with 300 ng TetR-mCherry plasmid using 2 µl of 
Lipofectamine® 2000 (Life Technologies) according to the manufacturer’s instructions. 
Then, 2 h after transfection, the medium was changed to DMEM with or without 50 µM 
dox, and the cells were incubated at 37°C and 5% CO2 for 24 h. Further, cells were 
fixed in 3,7% formaldehyde at room temperature (RT) for 10 minutes followed by 
permeabilization with 0.5% triton X-100 in 1xPBS for 10 minutes at RT. Cells were then 
washed three times with 1xPBS and stained with 4′,6-diamidino-2-phenylindole (DAPI) 
dye (1 µg/mL in water; Thermo Scientific) and washed three times with 1xPBS. Next, 
coverslips were mounted with mounting medium (Thermo Scientific). All experiments 
were carried out on a Zeiss Axiovert 200 M inverted microscope using a 20x/0.5 NA or 
63x/1.4 NA oil objective lens (Zeiss). Excitation was done using the mercury arc lamp 
(Zeiss). The filters used were 350/50 (excitation) and 460/50 (emission) for DAPI, 
482/18 (excitation) and 520/28 (emission) for EGFP and 565/30 (excitation) and 
620/60 (emission) for mCherry and mito tracker (ab176831, abcam). Images were 
repeated in three independent experiments. The data processing were performed 
using ImageJ. 
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7 Appendix 
 
Table 7.1 List of abbreviations.   
 
Abbreviation Meaning
% (w/v) % (weight/ volume)
°C degrees Celsius
µg microgramm
µL microliter
µM micromolar
3SS 3' splice site
5SS 5' splice site
5’ UTR 5' untranslated region
A adenine
AS alternative splicing
amp Ampicilin
BP branch point sequence
C cytosine
cDNA complementary DNA
CI chimeric intron 
CP cytosolic protein
DMEM Dulbecco's Modified Eagle Medium
DNA deoxyribonucleic acid
dNTP desoxynucleoside triphosphate
EGFP enhanced green fluorescent protein
FCS fetal calf serum
FRT Flp-In recombination target
F forward
G guanine
GOI gene of interest 
kb kilobases
min minutes
mL mililiter
mM milimolar
mRNA messenger RNA
nm nanometer
nM nanomolar
nt nucleotide
ORF open reading frame
P2A 2A ‘self-cleaving’ peptide from the porcine teschovirus-1 
PBS phosphate buffered saline
PCR polymerase chain reaction
Polypyrimidine Py
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R reverse
RNA ribonucleic acid
rpm rounds per minute
RT room temperature
s seconds
SELEX Systematic Evolution of Ligands by Exponential Enrichment
snRNPs small nuclear ribonucleoproteins 
T thymine
TetR tetracycline repressor 
TSD TetR Splicing Device 
U uracil
uORF upstream open reading frame
UV ultra violet
  References  
[83] 
 
8 References  
1. Qian, Y., McBride, C. & Del Vecchio, D. Programming Cells to Work for Us. 
Annu. Rev. Control. Robot. Auton. Syst. 1, 4.1-4.30 (2018). 
2. Slomovic, S., Pardee, K. & Collins, J. J. Synthetic biology devices for in vitro and 
in vivo diagnostics. Proc. Natl. Acad. Sci. 112, 14429–14435 (2015). 
3. Vecchio, D. Del, Dy, A. J. & Qian, Y. Control Theory Meets Synthetic Biology. 
(2016). doi:http://dx.doi.org/10.1098/rsif.2016.0380 
4. Ding, Y., Wu, F. & Tan, C. Synthetic Biology: A Bridge between Artificial and 
Natural Cells. Life 4, 1092–1116 (2014). 
5. Elowitz, M. B. & Leibier, S. A synthetic oscillatory network of transcriptional 
regulators. Nature 403, 335–338 (2000). 
6. Gardner, T. S., Cantor, C. R. & Collins, J. J. Construction of a genetic toggle 
switch in Escherichia coli. Nature 403, 339–342 (2000). 
7. Vazquez-Anderson, J. & Contreras, L. M. Regulatory RNAs: Charming gene 
management styles for synthetic biology applications. RNA Biol. 10, 1778–1797 
(2013). 
8. Purnick, P. E. M. & Weiss, R. The second wave of synthetic biology: From 
modules to systems. Nat. Rev. Mol. Cell Biol. 10, 410–422 (2009). 
9. Lewis, D. D., Villarreal, F. D., Wu, F. & Tan, C. Synthetic Biology Outside the 
Cell: Linking Computational Tools to Cell-Free Systems. Front. Bioeng. 
Biotechnol. 2, (2014). 
10. Mathur, M., Xiang, J. S. & Smolke, C. D. Mammalian synthetic biology for 
studying the cell. J. Cell Biol. 216, 73–82 (2017). 
11. Bird, A. et al. Multi-Input RNAi-Based Logic Circuit. 1307–1312 (2011). 
12. Din, M. O. et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature 
536, 81–85 (2016). 
13. Wei, P. et al. Bacterial virulence proteins as tools to rewire kinase pathways in 
yeast and immune cells. Nature 488, 384–388 (2012). 
14. Chakravarti, D. & Wong, W. W. Synthetic biology in cell-based cancer 
immunotherapy. Trends Biotechnol. 33, 449–461 (2015). 
15. Saxena, P. et al. A programmable synthetic lineage-control network that 
differentiates human IPSCs into glucose-sensitive insulin-secreting beta-like 
cells. Nat. Commun. 7, 1–14 (2016). 
16. Chappell, J., Watters, K. E., Takahashi, M. K. & Lucks, J. B. A renaissance in 
RNA synthetic biology: New mechanisms, applications and tools for the future. 
Curr. Opin. Chem. Biol. 28, 47–56 (2015). 
17. Cameron, D. E., Bashor, C. J. & Collins, J. J. A brief history of synthetic biology. 
Nat. Rev. Microbiol. 12, 381–390 (2014). 
18. Groher, F. & Suess, B. Synthetic riboswitches - A tool comes of age. Biochim. 
Biophys. Acta - Gene Regul. Mech. 1839, 964–973 (2014). 
19. Hallberg, Z. F., Su, Y., Kitto, R. Z. & Hammond, M. C. Engineering and In Vivo 
Applications of Riboswitches. Annu. Rev. Biochem 86, 515–39 (2017). 
20. Chappell, J. et al. The centrality of RNA for engineering gene expression. 
  References  
[84] 
 
Biotechnol. J. 8, 1379–1395 (2013). 
21. Chen, Y. Y. et al. Synthetic biology: advancing biological frontiers by building 
synthetic systems. Genome Biol. 13, 240 (2012). 
22. McKeague, M., Wong, R. S. & Smolke, C. D. Opportunities in the design and 
application of RNA for gene expression control. Nucleic Acids Res. 44, 2987–
2999 (2016). 
23. Engreitz, J. M., Ollikainen, N. & Guttman, M. Long non-coding RNAs: Spatial 
amplifiers that control nuclear structure and gene expression. Nat. Rev. Mol. Cell 
Biol. 17, 756–770 (2016). 
24. Dykes, I. M. & Emanueli, C. Transcriptional and Post-transcriptional Gene 
Regulation by Long Non-coding RNA. Genomics, Proteomics Bioinforma. 15, 
177–186 (2017). 
25. Kaphingst, K. A., Persky, S. & Lachance, C. NIH Public Access. 14, 384–399 
(2010). 
26. Beisel, C. L. & Storz, G. Networks. FEMS Microbiol. Rev. 34, 866–882 (2011). 
27. Levine, E., Zhang, Z., Kuhlman, T. & Hwa, T. Quantitative characteristics of gene 
regulation by small RNA. PLoS Biol. 5, 1998–2010 (2007). 
28. Seto, A. G., Kingston, R. E. & Lau, N. C. The Coming of Age for Piwi Proteins. 
Mol. Cell 26, 603–609 (2007). 
29. Jusiak, B., Cleto, S., Perez-Piñera, P. & Lu, T. K. Engineering Synthetic Gene 
Circuits in Living Cells with CRISPR Technology. Trends Biotechnol. 34, 535–
547 (2016). 
30. Serganov, A. & Nudler, E. A decade of riboswitches. Cell 152, 17–24 (2013). 
31. Berens, C., Groher, F. & Suess, B. RNA aptamers as genetic control devices: 
The potential of riboswitches as synthetic elements for regulating gene 
expression. Biotechnol. J. 10, 246–257 (2015). 
32. Winkler, W. C., Nahvi, A., Sudarsan, N., Barrick, J. E. & Breaker, R. R. An mRNA 
structure that controls gene expression by bindingS-adenosylmethionine. Nat. 
Struct. Mol. Biol. 10, 701–707 (2003). 
33. Wittmann, A. & Suess, B. Engineered riboswitches: Expanding researchers’ 
toolbox with synthetic RNA regulators. FEBS Lett. 586, 2076–2083 (2012). 
34. Winkler, W. C., Nahvi, A., Roth, A., Collins, J. A. & Breaker, R. R. Control of gene 
expression by a natural metabolite-responsive ribozyme. Nature 428, 281–286 
(2004). 
35. Kim, J. N. & Breaker, R. R. Purine sensing by riboswitches. Biol. Cell 100, 1–11 
(2008). 
36. Barrick, J. E. & Breaker, R. R. The distributions, mechanisms, and structures of 
metabolite-binding riboswitches. Genome Biol. 8, (2007). 
37. Garst, A. D., Edwards, A. L. & Batey, R. T. Riboswitches: Structures and 
mechanisms. Cold Spring Harb. Perspect. Biol. 3, 1–13 (2011). 
38. Breaker, R. R. Riboswitches and the RNA world. Cold Spring Harb. Perspect. 
Biol. 4, 1–15 (2012). 
39. Wachter, A. et al. Riboswitch Control of Gene Expression in Plants by Splicing 
and Alternative 3’ End Processing of mRNAs. Plant Cell Online 19, 3437–3450 
  References  
[85] 
 
(2007). 
40. Zhuo, Z. et al. Recent advances in SELEX technology and aptamer applications 
in biomedicine. Int. J. Mol. Sci. 18, 1–19 (2017). 
41. Suess, B. & Weigand, J. E. Nucleic Acid and Peptide Aptamers. 535, 201–208 
(2009). 
42. Wachsmuth, M. et al. Design criteria for synthetic riboswitches acting on 
transcription. RNA Biol. 12, 221–231 (2015). 
43. Topp, S. & Gallivan, J. P. Guiding Bacteria with Small Molecules and RNA 
Guiding Bacteria with Small Molecules and RNA. 129, 6807–6811 (2007). 
44. Wachsmuth, M., Findeiß, S., Weissheimer, N., Stadler, P. F. & Mörl, M. De novo 
design of a synthetic riboswitch that regulates transcription termination. Nucleic 
Acids Res. 41, 2541–2551 (2013). 
45. Ceres, P., Garst, A. D., Marcano-Velázquez, J. G. & Batey, R. T. Modularity of 
select riboswitch expression platforms enables facile engineering of novel 
genetic regulatory devices. ACS Synth. Biol. 2, 463–472 (2013). 
46. Ceres, P., Trausch, J. J. & Batey, R. T. Engineering modular ‘ON’ RNA switches 
using biological components. Nucleic Acids Res. 41, 10449–10461 (2013). 
47. Yen, L. et al. Exogenous control of mammalian gene expression through 
modulation of RNA self-cleavage. Nature 431, 471–476 (2004). 
48. Win, M. N. & Smolke, C. D. A modular and extensible RNA-based gene-
regulatory platform for engineering cellular function. Proc. Natl. Acad. Sci. 104, 
14283–14288 (2007). 
49. Wieland, M. & Hartig, J. S. Improved aptazyme design and in vivo screening 
enable riboswitching in bacteria. Angew. Chemie - Int. Ed. 47, 2604–2607 
(2008). 
50. Werstuck, G. & Green, M. R. Controlling gene expression in living cells through 
small molecule-RNA intera ... Library (Lond). 282, 296–298 (1998). 
51. Grate, D. & Wilson, C. Inducible regulation of the S. cerevisiae cell cycle 
mediated by an RNA aptamer-ligand complex. Bioorganic Med. Chem. 9, 2565–
2570 (2001). 
52. Weigand, J. E. et al. Screening for engineered neomycin riboswitches that 
control translation initiation. RNA 14, 89–97 (2008). 
53. Harvey, I., Garneau, P. & Pelletier, J. Inhibition of translation by RNA-small 
molecule interactions. Rna 8, 452–463 (2002). 
54. Ogawa, A. Rational design of artificial riboswitches based on ligand-dependent 
modulation of internal ribosome entry in wheat germ extract and their 
applications as label-free biosensors. Rna 17, 478–488 (2011). 
55. Bocobza, S. et al. Riboswitch-dependent gene regulation and its evolution in the 
plant kingdom Riboswitch-dependent gene regulation and its evolution in the 
plant kingdom. 2874–2879 (2007). doi:10.1101/gad.443907 
56. Cheah, M. T., Wachter, A., Sudarsan, N. & Breaker, R. R. Control of alternative 
RNA splicing and gene expression by eukaryotic riboswitches. Nature 447, 497–
500 (2007). 
57. Croft, M. T., Moulin, M., Webb, M. E. & Smith, A. G. Thiamine biosynthesis in 
  References  
[86] 
 
algae is regulated by riboswitches. Proc. Natl. Acad. Sci. 104, 20770–20775 
(2007). 
58. Kim, D.-S., Gusti, V., Pillai, S. G. & Gaur, R. K. An artificial riboswitch for 
controlling pre-mRNA splicing. RNA 11, 1667–1677 (2005). 
59. Kim, D.-S., Gusti, V., Dery, K. J. & Gaur, R. K. Ligand-induced sequestering of 
branchpoint sequence allows conditional control of splicing. BMC Mol. Biol. 9, 
23 (2008). 
60. Weigand, J. E. & Suess, B. Tetracycline aptamer-controlled regulation of pre-
mRNA splicing in yeast. Nucleic Acids Res. 35, 4179–4185 (2007). 
61. Vogel, M., Weigand, J. E., Kluge, B., Grez, M. & Suess, B. A small, portable RNA 
device for the control of exon skipping in mammalian cells. Nucleic Acids Res. 
1–12 (2018). doi:10.1093/nar/gky062 
62. Ausländer, S., Ketzer, P. & Hartig, J. S. A ligand-dependent hammerhead 
ribozyme switch for controlling mammalian gene expression. Mol. Biosyst. 6, 807 
(2010). 
63. Beilstein, K., Wittmann, A., Grez, M. & Suess, B. Conditional Control of 
Mammalian Gene Expression by Tetracycline-Dependent Hammerhead 
Ribozymes. ACS Synth. Biol. 4, 526–534 (2015). 
64. Klauser, B., Atanasov, J., Siewert, L. K. & Hartig, J. S. Ribozyme-Based 
Aminoglycoside Switches of Gene Expression Engineered by Genetic Selection 
in S. cerevisiae. ACS Synth. Biol. 4, 516–525 (2015). 
65. Nomura, Y., Zhou, L., Miu, A. & Yokobayashi, Y. Controlling mammalian gene 
expression by allosteric hepatitis delta virus ribozymes. ACS Synth. Biol. 2, 684–
689 (2013). 
66. Krol, J., Loedige, I. & Filipowicz, W. The widespread regulation of microRNA 
biogenesis, function and decay. Nat. Rev. Genet. 11, 597–610 (2010). 
67. Kurreck, J. RNA interference: From basic research to therapeutic applications. 
Angew. Chemie - Int. Ed. 48, 1378–1398 (2009). 
68. Atanasov, J., Groher, F., Weigand, J. E. & Suess, B. Design and implementation 
of a synthetic pre-miR switch for controlling miRNA biogenesis in mammals. 
Nucleic Acids Res. 45, e181 (2017). 
69. Beisel, C. L., Bayer, T. S., Hoff, K. G. & Smolke, C. D. Model-guided design of 
ligand-regulated RNAi for programmable control of gene expression. Mol. Syst. 
Biol. 4, (2008). 
70. Tuleuova, N., An, C. Il, Ramanculov, E., Revzin, A. & Yokobayashi, Y. 
Modulating endogenous gene expression of mammalian cells via RNA-small 
molecule interaction. Biochem. Biophys. Res. Commun. 376, 169–173 (2008). 
71. Kumar, D., An, C. Il & Yokobayashi, Y. Conditional RNA interference mediated 
by allosteric ribozyme. J. Am. Chem. Soc. 131, 13906–13907 (2009). 
72. Aragiannis, P., Ujita, Y. & Aito, H. RNA-based gene circuits for cell regulation. 
Proc. Jpn. Acad. 92, 412–422 (2016). 
73. Wroblewska, L. et al. Mammalian synthetic circuits with RNA binding proteins for 
RNA-only delivery. Nat. Biotechnol. 33, 839–841 (2015). 
74. Culler, S. J., Hoff, K. G. & Smolke, C. D. Reprogramming cellular behavior with 
  References  
[87] 
 
RNA controllers responsive to endogenous proteins. Science (80-. ). 330, 1251–
1255 (2010). 
75. Wang, Y., Cheong, C. G., Tanaka Hall, T. M. & Wang, Z. Engineering splicing 
factors with designed specificities. Nat. Methods 6, 825–830 (2009). 
76. Cooke, A., Prigge, A., Opperman, L. & Wickens, M. Targeted translational 
regulation using the PUF protein family scaffold. Proc. Natl. Acad. Sci. 108, 
15870–15875 (2011). 
77. Sprengel, R. & Hasan, M. T. Tetracycline-controlled genetic switches. Handb. 
Exp. Pharmacol. 178, 49–72 (2007). 
78. Orth, P., Schnappinger, D., Hillen, W., Saenger, W. & Hinrichs, W. Structural 
basis of gene regulation by the tetracycline inducible Tet repressor-operator 
system. Nat. Struct. Biol. 7, 215–9 (2000). 
79. Ramos, J. L. et al. The TetR Family of Transcriptional Repressors The TetR 
Family of Transcriptional Repressors. Microbiol. Mol. Biol. Rev. 69, 326–356 
(2005). 
80. Tiebel, B., Aung-Hilbrich, L. M., Schnappinger, D. & Hillen, W. Conformational 
changes necessary for gene regulation by Tet repressor assayed by reversible 
disulfide bond formation. EMBO J. 17, 5112–5119 (1998). 
81. Berens, C. & Hillen, W. Gene regulation by tetracyclines: Constraints of 
resistance regulation in bacteria shape TetR for application in eukaryotes. Eur. 
J. Biochem. 270, 3109–3121 (2003). 
82. Hunsicker, A. et al. An RNA Aptamer that Induces Transcription. Chem. Biol. 16, 
173–180 (2009). 
83. Müller, M., Weigand, J. E., Weichenrieder, O. & Suess, B. Thermodynamic 
characterization of an engineered tetracycline-binding riboswitch. Nucleic Acids 
Res. 34, 2607–2617 (2006). 
84. Steber, M., Arora, A., Hofmann, J., Brutschy, B. & Suess, B. Mechanistic basis 
for RNA aptamer-based induction of TetR. ChemBioChem 12, 2608–2614 
(2011). 
85. Tiebel, B. et al. Domain motions accompanying Tet repressor induction defined 
by changes of interspin distances at selectively labeled sites. J. Mol. Biol. 290, 
229–240 (1999). 
86. Goldfless, S. J., Belmont, B. J., De Paz, A. M., Liu, J. F. & Niles, J. C. Direct and 
specific chemical control of eukaryotic translation with a synthetic RNA-protein 
interaction. Nucleic Acids Res. 40, (2012). 
87. Goldfless, S. J., Wagner, J. C. & Niles, J. C. Versatile control of Plasmodium 
falciparum gene expression with an inducible protein–RNA interaction. Nat. 
Commun. 5, 5329 (2014). 
88. Ausländer, D., Wieland, M., Ausländer, S., Tigges, M. & Fussenegger, M. 
Rational design of a small molecule-responsive intramer controlling transgene 
expression in mammalian cells. Nucleic Acids Res. 39, (2011). 
89. Will, C. L. & Lührmann, R. Spliceosome structure and function. TL  - 3. Cold 
Spring Harb. Perspect. Biol. 3 VN-re, 1–23 (2011). 
90. Wahl, M. C., Will, C. L. & Lührmann, R. The Spliceosome: Design Principles of 
  References  
[88] 
 
a Dynamic RNP Machine. Cell 136, 701–718 (2009). 
91. Pérez-Valle, J. & Vilardell, J. Intronic features that determine the selection of the 
3′ splice site. Wiley Interdiscip. Rev. RNA 3, 707–717 (2012). 
92. Faustino, N. A., Cooper, T. a & Andre, N. Pre-mRNA splicing and human 
disease. Genes Dev. 17, 419–437 (2003). 
93. Ast, G. How did alternative splicing evolve? Nat. Rev. Genet. 5, 773–782 (2004). 
94. SM, B. Exon recognition in vertebrate splicing. Mol Cell Biol 2411–4 (1995). 
95. Smith, C. W. J. & Valcárcel, J. Alternative pre-mRNA splicing: the logic of 
combinatorial control. Trends Biochem. Sci. 25, 381–388 (2000). 
96. Chabot, B. Directing alternative splicing: Cast and scenarios. Trends Genet. 12, 
472–478 (1996). 
97. Scotti, M. M. & Swanson, M. S. RNA mis-splicing in disease. Nat. Rev. Genet. 
17, 19–32 (2015). 
98. Venables, J. P. Aberrant and Alternative Splicing in Cancer Aberrant and 
Alternative Splicing in Cancer. 64, 7647–7654 (2004). 
99. López-Bigas, N., Audit, B., Ouzounis, C., Parra, G. & Guigó, R. Are splicing 
mutations the most frequent cause of hereditary disease? FEBS Lett. 579, 1900–
1903 (2005). 
100. Baralle, D., Lucassen, A. & Buratti, E. Missed threads. Organization (2009). 
doi:10.1038/embor.2009.170 
101. Cooper, T. A., Wan, L. & Dreyfuss, G. RNA and Disease. Cell 136, 777–793 
(2009). 
102. Warf, M. B., Diegel, J. V, von Hippel, P. H. & Berglund, J. A. The protein factors 
MBNL1 and U2AF65 bind alternative RNA structures to regulate splicing. Proc. 
Natl. Acad. Sci. U. S. A. 106, 9203–9208 (2009). 
103. Groher, F. Kontrolle des prä-mRNA Spleißens durch synthetische 
Riboswitche.Dostoral thesis. 2015. TU Darmstadt, Department of Biology. 
104. Kærn, M., Elston, T. C., Blake, W. J. & Collins, J. J. Stochasticity in gene 
expression: From theories to phenotypes. Nat. Rev. Genet. 6, 451–464 (2005). 
105. Balázsi, G., Van Oudenaarden, A. & Collins, J. J. Cellular decision making and 
biological noise: From microbes to mammals. Cell 144, 910–925 (2011). 
106. Roßmanith, J. & Narberhaus, F. Modular arrangement of regulatory RNA 
elements. RNA Biol. 14, 287–292 (2017). 
107. Rimoldi, V. et al. Dual Role of G-runs and hnRNP F in the Regulation of a 
Mutation-Activated Pseudoexon in the Fibrinogen Gamma-Chain Transcript. 
PLoS One 8, 1–11 (2013). 
108. Han, J. et al. SR Proteins Induce Alternative Exon Skipping through Their 
Activities on the Flanking Constitutive Exons. Mol. Cell. Biol. 31, 793–802 (2011). 
109. Wang, Y., Wang, F., Wang, R., Zhao, P. & Xia, Q. 2A self-cleaving peptide-based 
multi-gene expression system in the silkworm Bombyx mori. Sci. Rep. 5, 16273 
(2015). 
110. Liu, Z. et al. Systematic comparison of 2A peptides for cloning multi-genes in a 
polycistronic vector. Sci. Rep. 7, 2193 (2017). 
111. Morris, D. R. & Geballe,  a P. Upstream Open Reading Frames as Regulators of 
  References  
[89] 
 
mRNA Translation. Mol. Cell. Biol. 20, 8635–8642 (2000). 
112. Sachs, M. S. & Geballe, A. P. Downstream control of upstream open reading 
frames. Cold Spring Harb. Lab. Press 20, 915–921 (2006). 
113. Hinnebusch, A. G. Molecular Mechanism of Scanning and Start Codon Selection 
in Eukaryotes. Microbiol. Mol. Biol. Rev. 75, 434–467 (2011). 
114. Hill, R., Cautain, B., de Pedro, N. & Link, W. Targeting nucleocytoplasmic 
transport in cancer therapy. Oncotarget 5, (2014). 
115. Bauer, N. C., Doetsch, P. W. & Corbett, A. H. Mechanisms Regulating Protein 
Localization. Traffic 16, 1039–1061 (2015). 
116. Hung, M.-C. & Link, W. Protein localization in disease and therapy. J. Cell Sci. 
124, 3381–3392 (2011). 
117. Edalat, F. NIH Public Access. 40, 1301–1315 (2012). 
118. Kim, Y. H., Han, M.-E. & Oh, S.-O. The molecular mechanism for nuclear 
transport and its application. Anat. Cell Biol. 50, 77 (2017). 
119. Reverdatto, S. et al. Subcellular Protein Localisation in Health and Disease. Nat. 
Commun. 5, 1–7 (2016). 
120. Abil, Z., Gumy, L. F., Zhao, H. & Hoogenraad, C. C. Inducible Control of mRNA 
Transport Using Reprogrammable RNA-Binding Proteins. ACS Synth. Biol. 6, 
950–956 (2017). 
121. Belmont, B. J. & Niles, J. C. Inducible Control of Subcellular RNA Localization 
Using a Synthetic Protein-RNA Aptamer Interaction. PLoS One 7, (2012). 
122. Klemm, J. D., Beals, C. R. & Crabtree, G. R. Rapid targeting of nuclear proteins 
to the cytoplasm. Curr. Biol. 7, 638–644 (1997). 
123. Kudo, N. et al. Leptomycin B inactivates CRM1/exportin 1 by covalent 
modification at a cysteine residue in the central conserved region. Proc. Natl. 
Acad. Sci. 96, 9112–9117 (1999). 
124. Kakar, M., Davis, J. R., Kern, S. E. & Lim, C. S. Optimizing the protein switch: 
Altering nuclear import and export signals, and ligand binding domain. J. Control. 
Release 120, 220–232 (2007). 
125. Beyer, H. M. et al. Red Light-Regulated Reversible Nuclear Localization of 
Proteins in Mammalian Cells and Zebrafish. ACS Synth. Biol. 4, 951–958 (2015). 
126. Niopek, D. et al. Engineering light-inducible nuclear localization signals for 
precise spatiotemporal control of protein dynamics in living cells. Nat. Commun. 
5, 1–11 (2014). 
127. Zillmann, M., Zapp, M. L. & Berget, S. M. Gel electrophoretic isolation of splicing 
complexes containing U1 small nuclear ribonucleoprotein particles. Mol. Cell. 
Biol. 8, 814–21 (1988). 
128. Meyer, M., Plass, M., Pérez-Valle, J., Eyras, E. & Vilardell, J. Deciphering 3’ss 
Selection in the Yeast Genome Reveals an RNA Thermosensor that Mediates 
Alternative Splicing. Mol. Cell 43, 1033–1039 (2011). 
129. Vigevani, L., Gohr, A., Webb, T., Irimia, M. & Valcárcel, J. Molecular basis of 
differential 3′ splice site sensitivity to anti-tumor drugs targeting U2 snRNP. Nat. 
Commun. 8, 1–15 (2017). 
130. Wu, W. et al. Alternative splicing controls nuclear translocation of the cell cycle-
  References  
[90] 
 
regulated Nek2 kinase. J. Biol. Chem. 282, 26431–26440 (2007). 
131. Cassago, A. et al. Mitochondrial localization and structure-based phosphate 
activation mechanism of Glutaminase C with implications for cancer metabolism. 
Proc. Natl. Acad. Sci. 109, 1092–1097 (2012). 
132. Hanson, S., Bauer, G., Fink, B. & Suess, B. Molecular analysis of a synthetic 
tetracycline-binding riboswitch Molecular analysis of a synthetic tetracycline-
binding riboswitch. RNA 11, 503–511 (2005). 
133. Koloteva, N., Müller, P. P. & McCarthy, J. E. G. The position dependence of 
translational regulation via RNA-RNA and RNA- protein interactions in the 5’-
untranslated region of eukaryotic mRNA is a function of the thermodynamic 
competence of 40 S ribosomes in translational initiation. J. Biol. Chem. 272, 
16531–16539 (1997). 
134. Suess, B. et al. Conditional gene expression by controlling translation with 
tetracycline-binding aptamers. Nucleic Acids Res. 31, 1853–1858 (2003). 
135. Goldfless, S. J., Belmont, B. J., De Paz, A. M., Liu, J. F. & Niles, J. C. Direct and 
specific chemical control of eukaryotic translation with a synthetic RNA-protein 
interaction. Nucleic Acids Res. 40, 1–12 (2012). 
136. Groher, F. et al. Riboswitching with ciprofloxacin—development and 
characterization of a novel RNA regulator. Nucleic Acids Res. 46, 2121–2132 
(2018). 
137. Davuluri, R. V, Suzuki, Y., Sugano, S. & Zhang, M. Q. CART Classification of 
Human 5 ′ UTR Sequences CART Classification of Human 5Ј UTR Sequences. 
Genome Res. 1807–1816 (2000). doi:10.1101/gr.GR-1460R 
138. Kötter, P., Weigand, J. E., Meyer, B., Entian, K.-D. & Suess, B. A fast and 
efficient translational control system for conditional expression of yeast genes. 
Nucleic Acids Res. 37, e120–e120 (2009). 
139. Del Vecchio, D., Ninfa, A. J. & Sontag, E. D. Modular cell biology: Retroactivity 
and insulation. Mol. Syst. Biol. 4, (2008). 
140. Pantoja-Hernández, L. & Martínez-García, J. C. Retroactivity in the Context of 
Modularly Structured Biomolecular Systems. Front. Bioeng. Biotechnol. 3, 85 
(2015). 
141. Buratti, E. & Baralle, F. E. Influence of RNA Secondary Structure on the Pre-
mRNA Splicing Process MINIREVIEW Influence of RNA Secondary Structure on 
the Pre-mRNA Splicing Process. Mol. Cell. Biol. 24, 10505–10514 (2004). 
142. Taggart, A. J., Desimone, A. M., Shih, J. S., Filloux, M. E. & Fairbrother, W. G. 
Large-scale mapping of branchpoints in human pre-mRNA transcripts in vivo. 
Nat. Struct. Mol. Biol. 19, 719–721 (2012). 
143. Horowitz, D. S. The mechanism of the second step of pre-mRNA splicing. Wiley 
Interdiscip. Rev. RNA 3, 331–350 (2012). 
144. Reich, C. I., VanHoy, R. W., Porter, G. L. & Wise, J. A. Mutations at the 3′ splice 
site can be suppressed by compensatory base changes in U1 snRNA in fission 
yeast. Cell 69, 1159–1169 (1992). 
145. Hallegger, M., Sobala, A. & Smith, C. W. J. Four exons of the serotonin receptor 
4 gene are associated with multiple distant branch points. 1–13 (2010). 
  References  
[91] 
 
doi:10.1261/rna.2013110.10 
146. Jenkins, J. L., Agrawal, A. A., Gupta, A., Green, M. R. & Kielkopf, C. L. U2AF65 
adapts to diverse pre-mRNA splice sites through conformational selection of 
specific and promiscuous RNA recognition motifs. Nucleic Acids Res. 41, 3859–
3873 (2013). 
147. Martin, R. M. et al. Principles of protein targeting to the nucleolus. Nucleus 6, 
314–325 (2015). 
148. Hink, M. A. et al. Structural dynamics of green fluorescent protein alone and 
fused with a single chain Fv protein. J. Biol. Chem. 275, 17556–17560 (2000). 
149. Lee, Y. J., Wei, H. M., Chen, L. Y. & Li, C. Localization of SERBP1 in stress 
granules and nucleoli. FEBS J. 281, 352–364 (2014). 
150. Karniely, S. & Pines, O. Single translation-dual destination: Mechanisms of dual 
protein targeting in eukaryotes. EMBO Rep. 6, 420–425 (2005). 
151. Fukasawa, Y. et al. MitoFates: Improved Prediction of Mitochondrial Targeting 
Sequences and Their Cleavage Sites. Mol. Cell. Proteomics 14, 1113–1126 
(2015). 
152. Koehler, C. M. Protein translocation pathways of the mitochondrion. FEBS Lett. 
476, 27–31 (2000). 
153. Kozak, M. Influences of mRNA secondary structure on initiation by eukaryotic 
ribosomes. Proc. Natl. Acad. Sci. 83, 2850–2854 (1986). 
154. Kozak, M. Features in the 5′ non-coding sequences of rabbit α and β-globin 
mRNAs that affect translational efficiency. J. Mol. Biol. 235, 95–110 (1994). 
155. Hentze, M. W. et al. Identification of the iron responsive element for the 
translational regulation of human ferritin mRNA. Science (80-. ). 238, 1570–1573 
(1987). 
156. Sonenberg, N. & Dever, T. E. Eukaryotic translation initiation factors and 
regulators. Curr. Opin. Struct. Biol. 13, 56–63 (2003). 
157. Gebauer, F. & Hentze, M. W. Molecular mechanisms of translational control. Nat. 
Rev. Mol. Cell Biol. 5, 827–835 (2004). 
158. Babendure, J. R., Babendure, J. L., Ding, J. & Tsien, R. Y. Control of mammalian 
translation by mRNA structure near caps Control of mammalian translation by 
mRNA structure near caps. Rna 12, 851–861 (2006). 
159. Schneider, C., Bronstein, L., Diemer, J., Koeppl, H. & Suess, B. ROC’n’Ribo: 
Characterizing a Riboswitching Expression System by Modeling Single-Cell 
Data. ACS Synth. Biol. 6, 1211–1224 (2017). 
160. Hanson, S., Berthelot, K., Fink, B., McCarthy, J. E. G. & Suess, B. Tetracycline-
aptamer-mediated translational regulation in yeast. Mol. Microbiol. 49, 1627–
1637 (2003). 
161. Ganesan, S. M., Falla, A., Goldfless, S. J., Nasamu, A. S. & Niles, J. C. Synthetic 
RNA–protein modules integrated with native translation mechanisms to control 
gene expression in malaria parasites. Nat. Commun. 7, 10727 (2016). 
162. Kopniczky, M. B., Moore, S. J. & Freemont, P. S. Multilevel Regulation and 
Translational Switches in Synthetic Biology. IEEE Trans. Biomed. Circuits Syst. 
9, 485–496 (2015). 
 References 
[92] 
163. Qi, L. S. et al. NIH Public Access. Curr. Opin. Cell Biol. 152, 1173–1183 (2013).
164. Agne, M. et al. Modularized CRISPR/dCas9 effector toolkit for target-specific
gene regulation. ACS Synth. Biol. 3, 986–989 (2014).
165. Lohmueller, J. J., Armel, T. Z. & Silver, P. A. A tunable zinc finger-based
framework for Boolean logic computation in mammalian cells. Nucleic Acids Res.
40, 5180–5187 (2012).
166. Garg, A., Lohmueller, J. J., Silver, P. A. & Armel, T. Z. Engineering synthetic TAL
effectors with orthogonal target sites. Nucleic Acids Res. 40, 7584–7595 (2012).
167. Olson, E. J. & Tabor, J. J. Post-translational tools expand the scope of synthetic
biology. Curr. Opin. Chem. Biol. 16, 300–306 (2012).
168. Westbrook, A. M. & Lucks, J. B. Achieving large dynamic range control of gene
expression with a compact RNA transcription-translation regulator. Nucleic Acids
Res. 45, 5614–5624 (2017).
169. Re, A. Synthetic Gene Expression Circuits for Designing Precision Tools in
Oncology. Front. Cell Dev. Biol. 5, 1–9 (2017).
170. Engstrom, M. D. & Pfleger, B. F. Transcription control engineering and
applications in synthetic biology. Synth. Syst. Biotechnol. 2, 176–191 (2017).
171. Ip, J. Y. et al. Global analysis of alternative splicing during T-cell activation.
Spring 563–572 (2007). doi:10.1261/rna.457207.attenuated
172. Arpino, J. A. J. et al. Tuning the dials of synthetic biology. Microbiol. (United
Kingdom) 159, 1236–1253 (2013).
173. Pfaffl, M. W. A new mathematical model for relative quantification in real-time
RT-PCR. Nucleic Acids Res. 29, 45e–45 (2001).
174. Berens, C. et al. Subtype selective tetracycline agonists and their application for
a two-stage regulatory system. ChemBioChem 7, 1320–1324 (2006).
 Talks and Poster presentations 
[93] 
9 Talks and Poster presentations 
2 nd International Caparica Conference in Splicing, Caparica-Lisbon, Portugal 2018 
Oral and Poster presentation 
MetaRNA: Discussions about science and the future, Darmstadt, Germany  2017 
Oral presentation  
The 22nd Annual Meeting of the RNA Society, Prague, Czech Republic 2017 
Poster presentation 
Aptamers 2017: 4rd Oxford symposium on Aptamers, Oxford, UK  2017 
Poster presentation  
MetaRNA: Midterm review, Copenhagen, Denmark   2017 
Oral presentation  
MetaRNA: Metabolism at the single-cell level, Groningen, Netherlands  2016 
Oral presentation  
1 st International Caparica Conference in Splicing, Caparica-Lisbon, Portugal 2016 
Poster presentation 
Aptamers 2016: 3rd Oxford symposium on Aptamers, Oxford, UK  2016 
Poster presentation  
MetaRNA: Riboswitch design, Darmstadt, Germany   2016 
Oral presentation  
MetaRNA: Aptamer selection and characterization, Bordeaux, France 2015 
Oral presentation  
FEBS-EMBO 2014 Conference, Paris, France  2014 
Poster presentation  
14th FEBS Young Scientists' Forum, Paris, France   2014 
Poster presentation  
XXI Molecular Biology Meeting, Barcelona, Spain  2014 
Oral presentation  
Barcelona BioMed Conference, Barcelona, Spain  2013 
Poster presentation  
3rd IRB PhD Student Symposium, Barcelona, Spain  2013 
Poster presentation  
 Talks and Poster presentations 
[94]
Publications
[95] 
10 Publications 
Mol, A. A., M. Vogel and B. Suess. 2020. Inducible nuclear import by TetR aptamer-
controlled 3' splice site selection. RNA DOI: 10.1261/rna.077453.120
Mol, A. A., F. Groher, B. Schreiber, C. Rühmkorff and B. Suess. 2019. Robust gene 
expression control in human cells with a novel universal TetR aptamer splicing module. 
Nucleic Acids Research, 47: https://doi.org/10.1093/nar/gkz753
Mol, A. A. and M. Stolarek. 2011. Induced damages of DNA by mutagens and the 
mechanisms of their formation. Advances in Cell Biology 38: 491-505  
Publications
[96]
Curriculum Vitae
[97] 
11 Curriculum Vitae 
Name: Adam Artur Mol  
Date of birth: 24th December 1988 in Tarnowskie Góry, Poland 
Address: Waldstrasse 43, 64354 Reinheim, Germany 
PROFESSIONAL EXPERIENCE 
Doctoral Candidate  2015-2018 
Research group: Synthetic Genetic Circuits, Department of Biology 
Technical University of Darmstadt (TUD), Darmstadt, Germany 
Doctoral thesis: A TetR-binding aptamer as versatile regulatory element 
Supervisor: Prof. Beatrix Suess 
Graduate Student 2012-2014 
Research group: Molecular mechanisms of pre-mRNA splicing  
Department of Molecular Genomics,  
Molecular Biology Institute of Barcelona (IBMB-CSIC), Barcelona, Spain 
Supervisor: Dr. Josep Vilardell  
Intern 2012 
State Sanitary-Epidemiological Inspection Bytom, Poland  
Organization and performance of sanitary and epidemiological examinations, 
surveys and tests, toxicological, and hygienic assessments and other types  
of expert analysis.  
Erasmus Intern 2011 
Research group: Control, evolution and genetic impact of plant transposons  
Department of Molecular Genetics  
The Center for Research in Agricultural Genomics (CRAG), Barcelona, Spain 
Supervisor: Dr. Josep Casacuberta  
Trainee 2009 
Department of Nuclear Medicine and Endocrine Oncology   
Centre of Oncology Maria Skłodowska-Curie Memorial Institute, Gliwice, Poland  
Participation in research focused on endocrine-related cancer, especially thyroid, parathyroid, 
adrenal glands and pituitary  
Supervisor: Prof. M.D. Barbara Jarząb  
EDUCATION 
M.Sc. in Biotechnology 2010-2012 
Department of Genetics, University of Silesia (US), Katowice, Poland  
Master thesis: In silico analysis and cloning of Hordeum vulgare AtNCED3, AtAHG2 and AtSAD1 homologs 
Supervisor: Prof. Dr. Mirosław Małuszyński and Dr. Agata Daszkowska-Golec  
Graduated Summa Cum Laude with perfect grade (6)  
Postgraduate Pedagogical Course - Biology Teacher 2009-2012 
University of Silesia, Katowice, Poland  
Faculty of Biology and Environmental Protection 
B.Sc. in Biotechnology 2007-2010 
Department of Genetics, University of Silesia (US), Katowice, Poland  
Bachelor thesis: Mutagen-induced damages of DNA and the mechanisms of their formation 
Supervisor: Prof. Dr. Mirosław Małuszyński  
Curriculum Vitae
[98]
Ehrenwörtliche Erklärung
[99] 
12 Ehrenwörtliche Erklärung 
Ich erkläre hiermit ehrenwörtlich, dass ich die vorliegende Arbeit entsprechend den 
Regeln guter wissenschaftlicher Praxis selbstständig und ohne unzulässige Hilfe 
Dritter angefertigt habe.  
Sämtliche aus fremden Quellen direkt oder indirekt übernommenen Gedanken sowie 
sämtliche von Anderen direkt oder indirekt übernommenen Daten, Techniken und 
Materialien sind als solche kenntlich gemacht. Die Arbeit wurde bisher bei keiner 
anderen Hochschule zu Prüfungszwecken eingereicht.  
Darmstadt, den 31.05.2018 
.............................................................................. 
(Adam Artur Mol) 
Ehrenwörtliche Erklärung
[100]
